Automated solution-phase synthesis of HIV- and Leishmania-associated oligosaccharides to probe structure-dependent immune responses by Song, Eun-ho
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2009
Automated solution-phase synthesis of HIV- and
Leishmania-associated oligosaccharides to probe
structure-dependent immune responses
Eun-ho Song
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Chemistry Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Song, Eun-ho, "Automated solution-phase synthesis of HIV- and Leishmania-associated oligosaccharides to probe structure-
dependent immune responses" (2009). Graduate Theses and Dissertations. 11053.
https://lib.dr.iastate.edu/etd/11053
Automated solution-phase synthesis of HIV- and Leishmania-associated 
oligosaccharides to probe structure-dependent immune responses 
 
 
 
 
 
by 
 
 
Eun-Ho Song 
 
 
 
A dissertation submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Major: Organic Chemistry 
 
Program of Study Committee: 
Nicola L. Pohl, Major Professor 
Richard C. Larock 
Malika Jeffries-EL 
Emily A. Smith 
Christine A. Petersen 
 
 
 
 
 
 
 
 
Iowa State University 
 
Ames, Iowa 
 
2009 
 
ii 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS iv 
  
ABSTRACT v 
  
CHAPTER 1. General introduction and review of fluorous-based   
carbohydrate microarrays 1 
     Dissertation organization 1 
     Fluorous-based small-molecule microarrays for protein, antibody and 
enzyme screening  3  
Overview of fluorous-based microarrays 3 
          Immobilization strategies for microarray fabrication 5 
          Noncovalent fluorous-based microarrays 9 
          Fluorous-based microarrays for protein and antibody screening 11 
          Fluorous-based microarrays for enzyme screening 14 
          Linking fluorous-based arrays to automated synthesis 16 
     References 18 
  
CHAPTER 2. Automated synthesis of HIV-associated linear α-1,2-linked 
pentamannose 24 
     Introduction 24 
     Results and discussion 26 
     Conclusion 27 
     Experimental section 28 
     References  34 
  
CHAPTER 3. Automated synthesis of Leishmania-associated carbohydrates 
 and fluorous-based microarrays 35 
     Introduction 35 
     Results and discussion 38 
     Conclusion 45 
     Experimental section 46 
     References 83 
  
CHAPTER 4. Development of automated synthesis and screening of 
phosphate-linked Leishmania-associated carbohydrates  86 
     Introduction 86 
iii 
     Results and discussion 90 
     Conclusion 96 
     Experimental section 97 
     References 132 
  
CHAPTER 5. Synthesis of multivalent Leishmania-associated capping 
carbohydrates and evaluation of structure-dependent immune responses in 
IL-12 production 135 
     Introduction 135 
     Results and discussion 138 
     Conclusion 145 
     Experimental section 146 
     References 165 
  
CHAPTER 6. Modification of degradable polymeric particles with 
carbohydrates for the study of in-vitro activation of dendritic cells  168 
     Introduction 168 
     Results and discussion 170 
     Conclusion  176 
     Experimental section 176 
     References 184 
  
CHAPTER 7. Conclusions and future directions 187 
  
ACKNOWLEDGMENTS 189 
  
APPENDIX A.  CHAPTER 2    1H AND 13C NMR SPECTRA 190 
  
APPENDIX B.  CHAPTER 3    1H AND 13C NMR SPECTRA 193 
  
APPENDIX C.  CHAPTER 4    1H AND 13C NMR SPECTRA 222 
  
APPENDIX D.  CHAPTER 5    1H AND 13C NMR SPECTRA 263 
  
APPENDIX E.  CHAPTER 6   1H AND 13C NMR SPECTRA 288 
 
 
  
iv 
LIST OF ABBREVIATIONS 
 
 
ACN acetonitrile 
AcOH acetic acid 
ESI-MS electrospray ionization mass spectrometry 
FMOC fluorenylmethoxycarbonyl 
FT-IR Fourier transform-infrared 
Gal galactose 
Glc glucose 
FITC fluorescein isothiocyanate 
GlcNAc N-acetylglucosamine 
Hepes N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
HPLC high pressure liquid chromatography 
(iPr)2NP(OBn)2 dibenzyl N,N-diisopropyl phosphoramidite 
ITC isothermal titration calorimetry 
IPP inorganic pyrophosphatase 
IPTG isopropyl thiogalactoside 
MALDI-TOF-MS matrix assisted laser desorption time-of-flight mass spectrometry 
Man mannose 
mCPBA 3-chloroperbenzoic acid 
m/z mass/charge ratio 
NAD+ nicotinamide adenine dinucleotide 
NADH nicotinamide adenine dinucleotide, reduced form 
NBS N-bromosuccinimide 
NDP nucleotide diphosphate 
NIS N-iodosuccinimide 
PEG polyethylene glycol 
Pi phosphate 
PPi pyrophosphate 
SIM selected ion monitoring 
TBDPS  tert-butyldiphenylsilyl 
TEA triethylamine 
TFA trifluoroacetic acid 
TfOH trifluoromethanesulfonic acid 
TMSOTf (trimethylsilyl)methanesulfonic acid 
  
  
v 
ABSTRACT 
Infectious disease associated-oligosaccharides are important target molecules for 
synthesis to enable studies of their functions in infection mechanisms both in humans 
and animals. Unlike solid-phase automated chemical syntheses of oligonucleotides 
and oligopeptides that serve to provide these molecules for systematic structure-
function relationships, automated chemical synthesis of oligosaccharides has been 
restricted due to the need to manage stereochemistry of each linkage and to the greater 
complexity of the monomeric carbohydrate building blocks. A new solution-phase 
automation platform that relies on fluorous solid-phase extraction (FSPE) to purify 
intermediates potentially offers easier access to complicated oligosaccharides with 
several features such as simpler monitoring of reactions, only 2-3 equivalents of 
building block usage per glycosylation cycle, labor savings, and easier access to 
previously constructed compounds. In addition, the fluorous allyl-tag used to simplify 
purification in the automation platform also allows not only direct incorporation into 
microarrays but also ready modification of the tag for facile conjugation to polymeric 
vehicles. Herein are reported the development of methods for this automation 
platform for the first construction of HIV- and Leishmania-associated 
vi 
oligosaccharides. Automated methods to make phosphate-linked sugars as well as 
conventional glycosidic linkages are demonstrated. Several Leishmania-associated 
oligosaccharides—including capping structures, phosphate-linked capping structures 
and phosphoglycan repeats—were synthesized as probes for carbohydrate microarrays 
to screen sera of infect animals. The further development of efficient conjugation 
chemistry allowed the multivalent modification of latex beads and degradable micro-
/nanoparticles with these bioactive oligosaccharides to probe carbohydrate-related 
structure/function relationships in the stimulation of cellular immune responses. 
 
 
 
 
 
 
 
 
1 
CHAPTER 1 
General introduction and review of fluorous-based carbohydrate 
microarrays 
Portions of this chapter have been published as a special report in Future Medicinal 
Chemistry (2009), 1, 889-896. (Copyright 2009 Future Science) 
1. Dissertation organization 
  This dissertation consists of seven chapters. The first chapter is a review published 
in Future Medicinal Chemistry in 2009. Chapter 1 includes not only recent progress in 
microarray fabrication methods in order to perform fluorous-based microarrays on 
both covalent and non-covalent immobilized slides but also applications of fluorous-
based microarrays in the screening of protein, antibody and enzyme activities. 
Chapter 2 describes the first automated solution-phase synthesis of HIV-associated 
linear α-1,2-linked pentamannose. Unlike solid phase-based automation platforms, 
the solution phase-based automation method allows the construction of 
oligosaccharides with easy reaction monitoring through conventional techniques such 
as thin layer chromatography (TLC) and high performance liquid chromatography 
(HPLC), fewer equivalents of building blocks per coupling cyclce (1.5 ~ 2 
2 
equivalents), and less laborious work. Chapter 3 discusses the automated synthesis of 
Leishmania-associated carbohydrates and fluorous-based microarray for antibody 
screening. Six different fluorous-tagged Leishmania-associated carbohydrates were 
synthesized either through automated synthesizer or iterative synthesis for antibody 
screening of serum using a fluorous-based microarray. Chapter 4 discusses the 
synthesis of phosphate-linked Leishmania-associated carbohydrates by using an H-
phosphonate strategy in order to investigate the role of phosphate-linkages in 
lipophosphoglycans (LPG). Importantly, the first automated synthesis of 
phosphoglycan repeats of L. donovani was achieved in a solution-based platform with 
the development of general protocols for this type of phosphate-linked carbohydrate.  
Chapter 5 includes the synthesis of multivalent Leishmania-associated capping 
carbohydrates for the collaborative evaluation of carbohydrate structure-dependent 
immune responses. Chapter 6 describes protocols for the modification of degradable 
polymeric particles with carbohydrates for the collaborative investigation of dendritic 
cell (DC) activation against carbohydrates-modified polymeric particles. Chapter 7 
provides conclusions for this dissertation as well as future directions for carbohydrate 
research. 
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2. Flurous–based small-molecule microarrays for protein, antibody and enzyme 
screening.  
Carbohydrates are one of the most abundant biomolecules on the surface of the cell 
membrane and thereby are crucial for the interactions of cells with one another and 
with pathogens such as viruses, bacteria, and fungi. Although several functions such 
as generating energy, mediating signal transduction between different organisms, and 
providing recognition makers and structural components have long been appreciated 
roles for carbohydrates, their regulation mechanisms are still not clear. Furthermore, 
the structural complexity of carbohydrates, which are derived from the incredible 
diversity of regiochemistries and stereochemistries possible between furanose and 
pyranose rings, adds to the difficulty in studying carbohydrate binding partners such 
as proteins, enzymes and antibodies.1 Given the limitations in accessing large 
quantities of pure structurally well-defined carbohydrates, carbohydrate microarrays 
are increasingly used as a versatile tool for unveiling the possible binding associates 
for carbohydrates since the first glycan array was reported in 1985.2 
 
2.1 Overview of fluorous-based microarrays. 
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 Small molecules are an important tool for the elucidation of biological 
recognition processes.3 Currently, the best way to design molecules that have 
biological activities for soluble proteins without structural information is to screen an 
assortment of possible structures. With increasing demand for useful tools for small 
molecule screening, small molecule microarrays have become increasingly important. 
Microarray techniques allow quick assessments of possible binding partners for 
biomolecules including nucleic acids, proteins and carbohydrates, with small amounts 
of sample and therefore lower costs than multiwell plate types of screening methods.  
Small molecule microarrays are particularly valuable for creating and probing 
multivalent displays of molecules such as saccharides that mimic the multivalent 
displays of cell-surface bound compounds. 
For example, carbohydrate microarrays have clearly played a key role in facilitating 
access to information about carbohydrate-protein interactions.4 After a general 
discussion of immobilization techniques used for small molecule microarray 
fabrication using carbohydrates as an example, a more detailed discussion of 
microarrays based on noncovalent fluorocarbon interactions will be surveyed to 
highlight the unique potential of fluorine in this context 
5 
2.2 Immobilization strategies for microarray fabrication 
 
 
 
 Figure 1. Representative covalent and noncovalent immobilization strategies for 
small molecules for microarray fabrication: a) Immobilization of thiol-functionalized 
molecules to maleimide-modified slides, b) Immobilization of amine-functionalized 
molecules to N-hydroxysuccinimide ester-modified slides, c) Immobilization of azide-
functionalized molecules to alkyne-modified slides by Huisgen cycloaddition, d) 
Immobilization through photochemical activation of natural products to aryl-diazirin-
coated slides, e)Immobilization of lipid-containing molecules to nitrocellulose, f) 
Immobilization of amine-functionalized molecules to noncovalently modified 
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polystyrene wells containing lipid-linked isocyanates, g) Immobilization of DNA-
tagged compounds to complementary strands on surface; h) Immobilization of 
fluorocarbon-tagged molecules to fluoroalkyl-modified slides.  
 Immobilization techniques for microarray formation can be divided into two 
main categories that describe the method of attachment of the molecules to the slide 
surface: covalent immobilization and noncovalent immobilization of the molecules to 
the slide surface. (Figure 1) A basic overview of these methods using carbohydrate 
immobilization as an example follows. Among covalent immobilization techniques, 
forming a stable bond between maleimide-functionalized slides and thiol-containing 
molecules5, 6, 7 is common, as well as reactions of amine-functionalized molecules 
with N-hydroxysuccinimde (NHS)-activated glass slides8, 9. Applications of Cu(I)-
mediated 1,3-dipolar Huisgen cycloadditions between azide-containing molecules and 
alkynylated glass slides10, 11, 12 have also been utilized to covalently attach 
carbohydrates or small molecules to slide surfaces for screening. When products 
contain hydroxyl or carboxylate moieties, photoinduced cross-linking based 
immobilization techniques13 have been introduced to array small molecules on 
diazirin-coated glass slides.14 Conditions (pH, time, temperature, etc.) have to be 
7 
optimized to maximize reaction yields of the covalent-bond forming step. The 
subsequent challenge is quantification of those yields to know the concentration of the 
molecules that will be screened. Each of these methods, of course, requires the 
introduction of the necessary functional group into both the molecules to be screened 
and the slides themselves. In certain cases in which the small molecules have unique 
reactive functional handles, at least unmodified molecules can be used with specially-
modified slides. For example, in addition to the photocrosslinking strategy mentioned 
above, the direct immobilization of unmodified reducing sugars recently has been 
shown using hydrazide- and aminoxy-derivatized glass slides.15 (Figure 2) Fifty-eight 
unmodified glycans including mono-, oligo- and polysaccharides were then directly 
arrayed on the specially derivatized slides and then tested for binding of the sugars to 
lectins, antibodies, and bacterial cells. Although undesired products such as acyclic 
adducts from hydrazide-derivatized slides and acyclic adducts with mixture of 
alpha/beta anomers from aminoxy-derivatized slides can be present at each 
microarray spot to complicate data interpretation, this one-step immobilization 
technique can be used to probe carbohydrate-protein binding, carbohydrate-antibody 
8 
binding and quantification of carbohydrate-protein binding without prior modification 
of the carbohydrates. 
 
 
  
Figure 2. One-step direct immobilization of unmodified reducing sugars to 
hydrazide- and aminoxy-modified slide surfaces. 
 
 Although covalent immobilization techniques have provided powerful tools for 
investigating the binding properties of molecules in microarray formats, noncovalent 
immobilization techniques are also being investigated (Figure 1). In contrast to 
covalent immobilization techniques, non-covalent techniques should render 
compounds on the slide surface more flexible, thus allowing them to move for optimal 
binding with a protein, antibody, or enzyme target. Moreover, non-covalent 
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immobilization techniques have the potential advantage of allowing the recycling and 
reuse of slides. 
 Several strategies have emerged for such noncovalent schemes to create 
carbohydrate microarrays. An intriguing noncovalent strategy involves attachment of 
a nucleic acid strand to a compound and then immobilization of that compound onto a 
specific location of a slide where a complementary nucleic acid strand is located.16 
The authors found their DNA-directed strategy to have a lower detection limit than a 
noncovalent strategy for detecting immobilized glycoconjugates. Older noncovalent 
immobilization strategies include the attachment of neoglycolipids (NGLs) on 
nitrocellulose17 and noncovalent arrays using long hydrocarbon chains18. The latter 
method requires amine-functionalized carbohydrates16 for an isocyanate-mediated 
capture strategy to attach the long hydrocarbon chains.19 Unfortunately, the use of 
such large hydrocarbon tags to noncovalently anchor compounds to the slide surface 
can be problematic, for example when detergents are required in bioassay buffers.   
 
2.3 Noncovalent fluorous-based microarrays 
10 
 
Figure 3. Application of fluorous-based microarrays for protein screening 
 
 More recently, noncovalent immobilization based on fluorophobic rather than 
hydrophobic effects has been tested in the context of microarray formation. Selective 
immobilization of a polyfluorocarbon (C8F17) chain attached to a carbohydrate to a 
fluorinated surface20,21,22,23 has been shown to be surprisingly robust enough for the 
screening of carbohydrate-protein binding screening (Figure 3). Prior to this work, 
such noncovalent fluorous interactions had been used to facilitate the purification of 
fluorous-tagged compounds from compounds that do not contain any fluorous content 
using fluorous solid-phase extraction (FSPE).24 Washing of fluorous-modified silica 
gel with aqueous/organic solvent mixtures allows retention of fluorous-tagged 
molecules, whereas non-fluorous compounds are eluted from the column. Organic 
solvents such as MeOH or THF then can elute fluorous-containing compounds. With 
this method, a compound with only a small fraction of fluorocarbon content (such as a 
single C6F13-containing tag) can be reliably purified. Although this tagging and 
protein
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11 
purification strategy has been used for the production of a range of bioactive 
molecules25, the fluorous tag normally has to be removed from compounds in order to 
use traditional screening methods. The first demonstration that this fluorous tag can 
be directly incorporated into a microarray platform opens new avenues to think about 
the production and screening of compounds and other uses for fluorous tags in 
biological applications.26, 27 To date, fluorous-based small molecule microarrays have 
shown utility for protein, antibody and enzyme screening. 
  
2.4 Fluorous-based microarrays for protein and antibody screening 
 Noncovalent fluorous-based microarrays possess unique features: 1) surface 
blocking steps after immobilization are rendered unnecessary and 2) high signal to 
noise ratios and low-nonspecific binding can be achieved with fewer washing steps 
than required with more reactive slide surfaces. In addition, the fluorocarbon tag itself 
does not complicate proton NMR spectra. The initial concept was developed in the 
context of carbohydrate microarray fabrication. Namely, fluorous-tagged 
monosaccharides were noncovalently immobilized by fluorous-fluorous interactions 
on a glass slide surface specially modified with C8F17 chains22. The immobilized 
12 
monosaccharides were screened with the common fluorescein isothiocyanate(FITC)-
labeled lectin concanavalin A (FITC-ConA) that is known to bind to alpha-linked 
mannose, glucose and N-acetylglucosamine. Indeed, specific binding of ConA to 
immobilized mannose and N-acetylglucosamine was observed by fluorescence 
imaging. More surprisingly, the use of detergents in the buffer used for screening of 
the sugars to a different lectin did not completely destroy the noncovalent interactions. 
Noncovalent fluorous-based arrays can clearly withstand detergents not tolerated by 
noncovalent hydrocarbon-based arrays. In further experiments, fluorous-based 
carbohydrate microarrays proved not only binding of ConA with two new 
carbohydrate ligands—both diastereomers of glycerol-D-manno-heptoses—but also 
facilitated the quantitative assessment of these carbohydrate-protein interactions.21 
Spring’s group28 has reported another application of fluorous-based microarrays 
for screening and probed the chain length requirement of the fluorous tag. By 
comparison of C8F17-tagged biotin with C6F13-tagged biotin, the longer C8F17-tag 
was considered more reliable for the attachment of biotin to the fluorous-coated glass 
slide. Enhanced biotin-avidin interactions on the fluorous-coated slide were achieved 
using a polyethylene glycol spacer between the biotin and the fluorous tag (C8F17). 
13 
This work demonstrated that not only very hydrophilic carbohydrates could be 
screened successfully in this new fluorous-based format, but also more lipophilic 
molecules such as biotin could be reliably immobilized. In addition, efficient 
protocols for recycling slides by washing with organic solvents such as methanol and 
dichloromethane were presented. 
 
Figure 4. Application of fluorous-based microarrays for antibody screening. 
 
 Microarrays are also showing promise as possible diagnostic tools in their 
detection of specific antibodies, for example against Globo-H antigens in human 
cancer sera11 or against Salmonella O-antigens in sera from Salmonella infected 
patients29. Recently, fluorous-tagged carbohydrate antigens associated with infectious 
diseases were synthesized using automated synthesis (see below). Serum samples 
from infected animals were incubated with the noncovalently immobilized sugars and 
then binding was visualized using fluorescently labeled secondary antibodies (Figure 
detect antibody-ligand interactions after incubation 
of fluorescently-labeled secondary antibodies
screening
fluorous-tagged (C8F17)-ligands 
on fluorous-coated slide
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4).30 The fluorous-based platform proved robust for the diagnosis of animals 
containing antibodies against the disease agent. These initial experiments show that 
fluorous-based microarrays can be used to diagnose animal exposure to pathogens. 
 
2.5 Fluorous-based microarrays for enzyme screening 
 Fluorus-based microarrays have also shown their use in screening for enzyme 
inhibitors and for enzyme activity. Small molecule microarrays were designed with 
compound to target a specific class of enzymes called histone deacetylases (HDACs). 
31
 To screen for inhibitors of this enzyme that catalyzes the hydrolysis of N-acetyl 
groups on lysine residues, fluorous-tagged compounds were printed on the fluorous-
coated glass surface and screened with HDAC2, HDAC3/NCoR3 peptide complex 
and HDAC8. Incubation of the arrays with alexa-647-labeled anti-His antibodies 
subsequently permitted visualization of HDAC binding by fluorescence imaging. This 
approach, which takes advantage of detecting native HDACs from whole cell lysates, 
could serve as the basis for the discovery of a range of new HDAC inhibitors. 
  
15 
 
Figure 5. Illustration of the Nimzyme assay. 32 
 
More recently, fluorous-tagged metabolites were applied to Nanostructure-
Initiator Mass Spectrometry (NIMS) for "on-chip" enzymatic assays.32 (Figure 5)  
The use of fluorous-phase immobilization for the attachment of enzyme substrates to 
fluorous-coated surfaces not only allowed high signal-to-noise ratios (S/N) in the 
analysis of the enzymatic reactions, but also allowed conformational flexibility to the 
substrates that likely enhance enzymatic activities. Specifically, immobilized 
fluorous–tagged lactose on the NIMS surface was used for direct characterization of 
beta-1,4-galactosidase activity from a thermophilic microbial community lysate. With 
the advances being made in mass spectrometry-based enzymatic assays based on 
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fhuorous-phase immobilization and NIMS, the construction of printed microarrays 
can also be imagined for the direct screening of enzymatic activity and inhibitors of 
that activity. 
 
2.6 Linking fluorous-based arrays to automated synthesis 
 
Solution-phase Automation Platform O
O
O
O
O
HPLC
F
F
O O O
O O O
Donor (1.5 ~ 3 eq)
Solid-phase Automation Platform
O O O
OOO
OO
O
O
O
OO
O
O
O
HPLC
Vs
Donor (5 ~ 20 eq)
Figure 6. Solution-phase automation platform vs Solid-phase automation platform. 
 
 All microarray formats are limited by the number of compounds that can be 
readily produced for inclusion in the particular array format. To date, no fluorous-
based microarray has incorporated hundreds or thousands of compounds. However, 
recent developments in the automation of multistep synthetic routes using fluorous-
17 
phase rather than solid-phase protocols promises to rapidly expand the availability of 
compounds already containing fluorous-tags required for their incorporation into 
fluorous-based microarrays (Figure 6).33,34 Although noncovalent fluorous 
interactions have been shown to be clearly robust enough to create a range of 
microarrays, the robustness of these interactions for repetitive robotics-based 
separations of a wide range of compounds is not obvious. However, these noncovalent 
interactions have proven reliable enough to separate intermediates in oligosaccharide 
synthesis on an automation platform with the same programmed protocol after 
investigations of parameter ranges. This new automation platform based on fluorous 
solid-phase extractions has been used to synthesize not only linear oligosaccharides, 
but also branched oligosaccharides. More recently, mono- and di-fluorous-tagged 
glucosamines have been examined for sequential separation using FSPE.35 Elution 
conditions could be found to obtain the desired di-tagged compound separate from the 
mono-tagged starting materials, thereby opening more possibilities for the automation 
of synthetic schemes that include less than optimal coupling results. Further 
applications of FSPE-based automation are now in progress for the construction of a 
18 
range of oligosaccharides to probe the scope and range of this new method to provide 
compounds already tagged for incorporation into fluorous-based screening protocols. 
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CHAPTER 2 
Automated synthesis of HIV-associated linear α-1,2-linked 
pentamannose 
Eun-Ho Song and Nicola L. Pohl 
Introduction 
Facile synthesis of oligosaccharide has been an issue both in organic synthesis and 
biomedical research due to difficulties in the construction of complicated 
oligosaccharides. With this demand, carbohydrate chemistry and automation method 
have quickly consolidated their position as practical and versatile method for the 
construction of oligosaccharide.  
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Figure 1. α–(1-2) linked pentamannose 
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Oligomannose has been considered as an important target molecule due to its 
unique structure and function as a GPI anchors in nature.1 In addition, poly α-
mannose has been well known as ligand for concanavalin A (Con A)2, one of 
important cell wall components 3,4 and HIV-associated carbohydrates on gp1205.      
Although the synthesis of oligomannose in an automation platform using solid 
phase has previously been reported by Seeberger’s group6, the efficiency of 
automation on the solid phase was not reliable due to several reasons such as 
consuming too much reagents (5 ~ 10 equiv of glycosyl donor per cycle) and 
difficulties of monitoring reaction. Recently, iterative synthesis of α–(1-2) linked 
tetramannose has been reported to probe the utilization of fluorous solid-phase 
extraction (FSPE) protocol in oligosaccharides synthesis.7 To increase the efficiency 
of automated platform, FSPE technique has been employed in automation platform 
and newly developed solution-phase automation platform8 enables using only 1.5 ~ 2 
equivalents of donor building blocks, monitoring the completion of reaction by TLC 
as well as easy purification through FSPE for facile synthesis of α–(1-2) linked 
pentamannose (Figure 1). 
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Herein, we present the utilization of solution-phase automation platform as a useful 
tool for the construction of HIV-associated linear oligomannose.  
 
Results and discussion  
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Figure 2. Automated synthesis of α–(1-2) linked pentamannose 
 
Fluorous-tagged mannose acceptor 49 has been prepared to improve the efficiency of 
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purification through FSPE10. Only 1.5 equivalent of trichloroacetimidate11 1 which 
can be activated under acidic condition (TMSOTf) has also been used as a glycosyl 
donor. The reaction has been done 3.5 cycles (4 x glycosylation, 3 x deacetylation and 
4 x FSPE)  for 24 h 56 min 39 sec without any labor since automated platform was 
ready to run the synthesizer for making liner pentamannose. (Figure 2)  Strikingly, 
not only 2 equiv of glycosyl donor per one cycle was consumed for the completion of 
glycosylation, but the purity of crude product 5 (18 mg) shown in HPLC traces 
(supporting information) after 7 steps (24 h 56 min 39 sec) was also remarkable even 
without further purification. Simple prep TLC gave us highly pure product (15 mg, 
73 % per step) to have reasonable 1H-, 13C-NMR and mass spectroscopy data. We 
evaluated the efficacy of solution-phase approach with a direct comparison of yield 
based on the glycosyl donor. While 27 % yield per glycosylation/deprotection cycle 
was produced in the solution-phase automation platform, only a 5 % per cycle yield 
was produced in the traditional solid-phase approach. Over many cycles, huge 
differences in building block loss will be produced.    
 
Conclusion 
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First solution-phase automated synthesis of HIV-associated linear pentamannose 
was achieved in the new solution-phase automation platform. In particular, fluorous-
tagged oligosacchrides from solution-phase automation platform can be incorporated 
into microarrays for screening antibody and protein in terms of diagnostic tool. These 
successful results suggest that the automation of oligosaccharide can be performed 
with small amount of reagents (2 equiv of glycosyl donor per cycle), less laborious 
work, and high purity of products. From these achievements, other complicated 
oligosaccharide can be introduced to the same automated platform.  
 
Experimental section 
General methods 
Solvents were reagent grade and in most cases dried prior to use. All other 
commercially available reagents were used as received unless otherwise noted. The 
organic extracts were dried over anhydrous MgSO4. Tetrahydrofuran (THF) was 
distilled from lithium aluminum hydride (LiAlH4) prior to use. Methylene chloride 
(CH2Cl2), and triethylamine (Et3N) were distilled from calcium hydride. Diethyl ether 
(Et2O) was distilled from sodium-benzophenone ketyl.  
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1H and 13C spectra NMR were obtained at 400 MHz and 100 MHz on Varian VXR-
400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an 
Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems 
QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per 
million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are 
reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.   
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   Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-O-benzyl-α-
D-mannopyranoside (2)9 
  To a solution of 2-O-acetyl-3,4,6-O-benzylyl-α-D-mannopyranosyl 
tricholoroacetimidate 111 (0.3 g, 0.47 mmol) and 3-
(perfluorooctyl)propanyloxybutenyl alcohol9 (0.13 g, 0.24 mmol) in dry 
30 
dichloroethane (5 mL) was added TMSOTf (8.5 µL, 0.05 mmol) at 25 oC. The 
reaction mixture was stirred at room temperature for 30 min. The reaction was 
quenched with triethylamine (0.5 mL) and concentrated under reduced pressure. The 
crude product was purified by solid phase extraction using fluoro flash column. 
Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired 
product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced 
pressure to obtain the desired product 2 (0.20 g, 84 %).  
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Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-2-hydroxy-α-D-
mannopyranoside (3)7
  To a solution of 3-(perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-O-benzyl- 
α-D-mannopyranoside  2 (0.2 g, 0.2 mmol) in  methanol was added Na (45 mg). 
The reaction mixture was stirred at 25 oC for 1 h and concentrated under reduced 
pressure. The crude product 3 was purified to obtain the desired product (0.19 g, 
31 
100 %) by silica column chromatography.   
 
ASW Pentamannose method run 
 After FSPE, the methanol elution collected in the vial was removed from the 
instrument and concentrated. Solvent was removed under reduced pressure to obtain 
the crude product (18 mg, 13 %) as colorless oil. In order to obtain pure product 5 (15 
mg, 11 %) for 1H NMR, 13 C NMR and mass spectrum, further purification was 
performed using prep TLC.  
Rf (ethyl acetate/haxane):  0.75 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.35-7.11 (m, 75 H), 5.61-5.58 (m, 2H), 5.55-
5.54 (m, 1H), 5.24 (d, J = 1.6, 1H), 5.23 (d, J = 1.2, 1H), 5.15 (d, J = 0.8, 1H), 5.03 (d, 
J = 0.8, 1H), 4.98 (d, J = 1.6 , 1H), 4.88-4.71 (m, 5H), 4.68-4.33 (m, 23 H), 4.22-4.06 
(m, 6H), 3.98-3.42 (m, 29 H), 3.33 (t, J = 6.4, 2H),  2.13-2.04 (m, 2H), 2.12 (s, 3H), 
1.82-1.74 (m, 2H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.3 (C=O), 138.8-138.2 (m, Cq-Aryl), 
128.6-127.5 (m, CH-Aryl), [101.6, 101.0, 99.7, 99.5, 98.7 (CHanomeric)], 79.9, 78.8, 
78.5, 77.5, 76.5,75.8, 75.5, 75.3, 75.2, 75.1, 74.9, 74.5, 73.5, 73.4, 73.0, 72.8, 72.4, 
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72.2, 72.1, 72.0, 71.9, 71.8, 69.9, 69.7, 68.9, 68.8, 66.7, 66.6, 62.9, 28.5, 28.2, 28.0, 
21.4, 21.1. 
HRMS-ESI (m/z): [M+Na]+Calcd for C152H155F17O28Na, 2775.8423; Found, 
2775.1026. 
 
- 3.5 cycles (24 h 56 min) completed for the synthesis of pentamannose. 
 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
2 
3 
4 
5 
 
6 
 
7 
8 
Glycosylation 
 
 
TLC sample 
Quenching 
Evaporation 
 
Deacetylation 
TLC sample 
Quenching 
Evaporation 
FSPE 
2 equivalent donor  (100 µmol) in 0.5 mL 
Toluene,  
1 equivalent F-tagged acceptor (50 µmol) in 1 
mL Toluene; 0.1 equivalent TMSOTf, rt 
30 µl of crude reaction mixture withdrawn 
0.5 ml TEA 
40 oC 
 
3 equivalent of NaOMe solution 
30 µl of crude reaction mixture withdrawn 
0.3 ml 0.5 M Acetic acid solution in MeOH 
50 oC 
30 min 
 
 
 
 
45 min 
  
2 h 
 
 
45 min 
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9 
10 
11 
12 
13 
14 
15 
preparation 
Sample 
loading 
         
Wash 
Wash 
Transfer 
Evaporation 
Transfer 
Evaporation 
 
 
0.4 ml DMF 
0.7 ml crude sample transferred to cartridge 
4.7 ml 80% methanol wash 
1.5 ml methanol wash (repeated 3 times) 
4.7 ml collected sample transferred to clean vial 
50 oC 
2 ml toluene added 
50 oC 
 
 
 
 
 
45 min 
 
45 min 
 
- HPLC traces of pentamannose run 
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CHAPTER 3 
Automated synthesis of Leishmania-associated carbohydrates and 
fluorous-based carbohydrate microarrays 
A paper to be submitted to Chemical Communications 
Eun-Ho Song and Nicola L. Pohl 
Introduction 
The increasing demand for oligosaccharides in the field of biomedical research led 
to the development of synthetic methods for the complicated oligosaccharide 
synthesis in the field of organic chemistry. Although several approaches, such as one-
pot solution-phase synthesis and solid-phase based automated synthesis, have been 
developed for facile synthesis of oligosaccharides,1,2 structurally complicated 
oligosaccharides are still not readily available in the market due to difficulties in the 
formation of a stereocenter upon connection with other sugars while customized DNA 
sequences and peptides are commercialized in the market.  
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Scheme 1. Fluorous phase-based automation platform and its applications. 
 
We have recently developed the first automation platform to carry out iterative 
synthesis based on fluorous-solid-phase extraction (FSPE) protocol3, rather than solid-
phase-based purification (Scheme 1). This new automation platform allows the use of 
5 to 10-fold lower building block amounts than the solid-phase approaches, but also 
enables easy monitoring of reaction by TLC. More importantly, fluorous-tagged 
products from fluorous phase-based automation platform are not only directly 
applicable in microarrays, but also capable of conjugation to ligands or other carriers.      
Leishmaniasis has been known as a parasitic disease caused by infection with over 
15 species of Leishmania. Leishmaniasis is mostly endemic throughout Africa, India, 
southern Europe, and Central and South America with an estimated 12 – 15 million 
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individuals and 2 million new cases each year. In order to prevent leishmaniasis, 
WHO have designated it as a category I (emerging and uncontrolled) disease.4 In spite 
of the significant effort made in the development of leishmaniasis vaccine, no vaccine 
against leishmaniasis is being made to support the prevention of disease.  
Cell-surface glycoconjugates are not only significant in the survival of the 
Leishmania parasite5, it also can be used as target in order to unveil the role of 
carbohydrates on the mechanism of infection. Lipophosphoglycan (LPG) is known as 
one of the major glycoconjygates in Leishmania.6 As shown in Figure 1, structure 
analysis of LPG has shown that it has three domains, a glycosylphosphatidylinositol 
(GPI) anchor, a repeating phosphorylated saccharide region, and an oligosaccharide 
cap structure.7,8 
But, the identification of structure-function relationship of the extracellular domain 
in LPG is still a challenge for both chemists and biologists. Although earlier reports 
for the synthesis of Leishmania capping structures have been featured in the 
construction of desired capping structures with different synthetic routs,9-13 
synthesized capping structures have never been prepared for microarrays. Early 
successes in microarrays for antibody binding were dedicated to detect specific 
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antibodies against Globo-H antigens in cancer patients’ sera14 or Salmonella O-
antigen in Salmonella infected patients’ sera15. However, because of limitations in 
availability of defined carbohydrate antigens and reliable tools, identifying 
interactions between carbohydrate antigens associated infectious diseases and 
antibody in serum from infected animals or human has been difficult.     
In this context, facile synthesis of oligosaccharides should be accomplished as 
prerequisite in order to economically achieve the rapid development of fluorous-based 
microarray technique which enables detection of various Leishmania species in a 
short time,   
Herein, we report the first solution-phase automated synthesis of Leishmania 
tetrasaccharide and iterative synthesis of Leishmania capping structures for the 
fluorous-based microarray of Leishmania capping structures as a possible diagnostic 
tool for the detection of antibodies in serum.  
 
Results and discussion 
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Figure 1. Fluorous alcohol and building blocks for the automated fluorous-phase 
synthesis of Leishmania tetrasaccharide. 
 
The automated synthesis of Leishmania tetrasaccharide was designed to use just 
two building blocks: a known activated mannose building block16 and a building 
block obtained from lactose (Figure 1). 
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Scheme 2. Synthesis of key disaccharide building block. (a) (i) CH2=CHCH2OH, 
TfOH, (ii) Na, MeOH (87 %); (b) (i) DMP DCM, (ii) NaBH4, CH2Cl2/MeOH (92 %); 
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(c) Ac2O, DMAP, TEA, CH2Cl2 (91 %); (d) [Ir] cat., H2, THF (94 %); (e) (i) HgO, 
HgCl2, O=(CH3)2/H2O (10/1), (ii) TCA, DBU, CH2Cl2 (89 %). 
 
The key intermediate hexa-O-benzyl orthoester 117 was prepared by orthester 
formation and follwed by benzylation from lactose in in good yield. One-step 
allylation under mild conditions using allyl alcohol and TfOH produced mainly 2-O-
unprotected saccharide 2 along with 2-O-acetylated saccharide. Further deprotection 
by NaOMe gave the desired 2-O-unprotected saccharide 2 in high yield (87% over 2 
steps). Conversion of β-glucoside 2 to α-mannoside 3 was achieved by a two-step 
oxidation-reduction process. Initial attempts to obtain 2-ulose 3 via Swern oxidation 
were unsatisfactory. Known oxidation condition18 using Ac2O/DMSO gave desired 
product in ~ 70 % yield, but it required long reaction time (48 h) and produced 
acetylated side product (5 ~ 10 %). However upon changing the oxidation conditions 
to Dess-Martin periodate, the reaction went smoothly at 35 oC for 3 h in quantitative 
yield. Further reduction with NaBH4 to invert the stereochemistry of the C2 position 
gave the desired disaccharide 3 in high yield (92 % over 2 steps). Acetylation of 3 
was performed under DMAP condition in 91 % yield. The allyl group 4 was removed 
41 
by isomerization to propenyl ether 5 with an iridium catalyst19 and subsequent 
hydrolysis20 under non-acidic conditions using HgO/HgCl2. The desired activated 
glycosyl donor 6 was then prepared as needed with trichloroacetonitrile/DBU. 
The important features of this approach include a suitable protecting group strategy, 
the transformation of glucose (Glc) to mannose (Man), and a fluorous solid-phase 
extraction (FSPE) technique for automation platform as an efficient purification 
method. 
Fluorous-tag 7 has been prepared to improve the efficiency of purification through 
FSPE. Trichloroacetimidates 6 and 8 that can be activated under acidic condition 
(TMSOTf) have also been used as a glycosyl donor. The reaction has been done 2.5 
cycles for 17 h 31 min without any labor since automated platform was ready to run 
the synthesizer for making Leshimania tetrasaccharide. (Scheme 3)  Strikingly, not 
only 2 eq of glycosyl donor per one cycle was consumed for the completion of 
glycosylation, but the purity of crude product 11 (30 mg) shown in HPLC traces 
(supporting information) after 5 steps (17 h 31 min) was also remarkable even without 
further purification. Simple prep TLC gave us highly pure product (21 mg, 71 % per 
step) to have reasonable 1H-, 13C-NMR and mass spectroscopy data. 
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Scheme 3. Automated fluorous-phase synthesis of Leishmania tetrasaccharide. 
 
These successful results demonstrated that the automation of oligosaccharide can 
be performed with small amount of reagents, less labor, and high purity of product. 
From these achievements, other oligosaccharide can be introduced to the same 
automated platform. 
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Scheme 4. Fluorous-tagged branched Tri- and Tetrasaccharide for microarray. 
 
Fully deprotected Fluorous-tagged branched trisaccharide 10-1 and tetrasaccharide 
11-1 were prepared after deacetylation, followed by simultaneous debenzylation and 
reduction of alkene with Pd/C/H2.   
 
Iterative synthesis of Leishmania capping structures 
Leishmania species such as L. major, L. donovani and L. mexicana have linear α-
1,2-linked mannose oligomer and lactose capping structures.7,8  Iterative synthesis of 
linear α-1,2-linked mannose oligomers has been done in order to complete libraries 
for Leishmania capping structures. Each glycosylation was performed with 1.1 
equivalent of donor rather than 1.5 equivalent of donor21 in toluene at 25 oC for 5 min. 
Facile purification of crude product by FSPE enabled easy preparation of desired 
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linear α-1,2-linked dimannose 13 and trimannose 14 in high yield.  
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Scheme 5. Iterative synthesis of linear mannose oligomer. 
 
Deacetylation, followed by simultaneous debenzylation and reduction of alkene 
with Pd/C/H2, gave desired fully deprotected fluorous–tagged α-1,2-linked di- and tri-
mannose in high yield (Scheme 6). 
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Scheme 6. Fluorous–tagged α-1,2-linked di- and tri-mannose.  
 
Although iterative synthesis of linear α-1,2-linked dimannose 13 and trimannose 14 
has previously been reported in good yield,21 these oligomers have never been 
produced for the application in fluorous-based microarrays.    
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Figure 3. Fluorous-tagged galactose and lactose for microarray. 
 
Fully deprotected fluorous-tagged galactose 15 and lactose 16 as L. donovani 
capping structures were also prepared as reported in the literature.22  
 
Conclusion 
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In conclusion, we have shown that fully deprotected Leishmania capping structures 
for L. donovani and L. major were efficiently syntheisized either through fluorous-
based automation platform or iterative synthesis using FSPE. Conversion of β-
glucoside to α-mannoside as a key step for the synthesis of disaccharide building 
block was achieved by Dess-Martin oxidation, followed by reduction with NaBH4 in 
high yield. Most importantly, automated fluorous-phase synthesis of Leishmania 
tetrasaccharide enabled facile synthesis of target oligosaccharides in order to be 
incorporated into fluorous-based microarray with high purity, less chemicals and less 
laborious work. This fluorous-based automated platform might be a powerful tool for 
the construction of carbohydrate library for the study of structure-function 
relationships.  
 
Experimental section 
General methods 
Solvents were reagent grade and in most cases dried prior to use. All other 
commercially available reagents were used as received unless otherwise noted. The 
organic extracts were dried over anhydrous MgSO4. Tetrahydrofuran (THF) was 
distilled from lithium aluminum hydride (LiAlH4) prior to use. Methylene chloride 
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(CH2Cl2), and triethylamine (Et3N) were distilled from calcium hydride. Diethyl ether 
(Et2O) was distilled from sodium-benzophenone ketyl.  
  
1H and 13C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-
400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an 
Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems 
QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per 
million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are 
reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.   
 
Synthesis of disaccharide building block 
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Synthesis of 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-1,2,3,6-tetra-O-
acetyl-D-glucopyranoside.19 
To a solution of lactose (1 g, 2.8 mmol) in acetic anhydride (10 mL) was added 
48 
catalytic amount of  iodine (14 mg, 0.1 mmol) at 25 oC. The reaction mixture was 
stirred at room temperature for 1 h. The dark brown reaction mixture was poured into 
a separatory funnel containing dichloromethane, aqueous sodium thiosulfate solution 
and crushed ice. The colorless solution from a separatory funnel was washed with 
H2O (2 x 50 mL) and sat.NaHCO3 (2 x 50 mL). It was dried with Na2SO4 and then 
concentrated under reduced vacuum to obtain the desired product with quantitative 
yield. 
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Synthesis of 2,3,4,6,-Tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-3,6-di-O-acetyl-
1,2-O-(1-methoxyethylidiene)-β-D-glucopyranoside.19  
To a solution of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-1,2,3,6-tetra-O-
acetyl-D-glucopyranoside (1.5 g, 2.2 mmol) in dichloromethane (5 mL) was added 
33 % HBr (5 mL, 28.6 mmol) in acetic acid for 10 min. The reaction mixture was 
stirred at 25 oC for 1 h and then checked TLC to check the completion of reaction. 
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After completion of reaction, the mixture was washed with cold water three times and 
then followed by washed with saturated sodium bicarbonate solution three times. The 
neutralized solution was dried with sodium sulfate and concentrated under reduced 
pressure. The crude product was used for next step without further purification. To a 
solution of hepta-acetyl lactosyl bromide in dichloromethane was added triethylamine 
(0.62 mL, 4.4 mmol), Bu4NBr (0.71 mg, 2.2 mmol) and methanol (0.077 mL, 2.64 
mmol). The reaction mixture was stirred at 40 oC for 16 h and then washed with H2O 
(1 x 50 mL). The solution was dried with Na2SO4 and then concentrated under 
reduced vacuum.  The crude produce was purified to obtain the desired product (1.19 
g, 83 % over 2 steps) by silica column chromatography.   
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Synthesis of 2,3,4,6,-Tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-3,6-di-O-benzyl-
1,2-O-(1-methoxyethylidiene)-β-D-glucopyranoside 1.19  
To a solution of 2,3,4,6,-tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-3,4-di-O-acetyl-
50 
1,2-O-(1-methoxyethylidiene)-β-D-glucopyranoside (1g, 1.5 mmol) in MeOH (5 mL) 
was added catalytic amount of Na (3.5 mg, 0.15 mmol) . The reaction mixture was 
stirred at 25 oC for 6 h and then concentrated under reduced vacuum to yield the crude 
deacetylated product as yellow foam. To a solution of deacetylated product in DMF 
(10 mL) was added 60 % NaH (0.47 g, 11.5 mmol), followed by addition of benzyl 
bromide (2.06 mL, 11.5 mmol) and tetrabuylammonium iodide (0.57 g, 1.5 mmol) at 
0 oC.  The reaction mixture was warmed up to 25 oC and stirred for 12 h. The 
reaction mixture was diluted with dichloromethane (20 mL) and then washed with 
H2O (2 x 50 mL). The organic layer was dried with Na2SO4 and concentrated under 
reduced vacuum. The crude product was purified by flash silica column 
chromatography to afford the desired product (1) (1.28 g, 89 % over 2 steps).  
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Synthesis of Allyl O-(2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-
hydroxy-3,6-di-O-benzyl-β-D-glucopyranoside 2. 
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  A solution of 2,3,4,6,-Tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-3,6-di-O-
benzyl-1,2-O-(1-methoxyethylidiene)-β-D-glucopyranoside (1) (1 g, 1.1 mmol) and 
ally alcohol (0.45 mL, 6.6 mmol) in dichloromethane (10 mL) was cooled to – 40 oC 
and TfOH (6 µL, 0.07 mmol) was added dropwise over 10 min. The reaction mixture 
was stirred at – 40 oC for 30 min and allowed to 25 oC for 1 h followed by, addition of 
triethylamine to neutralize a solution. The crude product was obtained after 
concentration of solvent under reduced vacuum. To a crude product in MeOH was 
added Na (5 mg, 0.22 mmol). The reaction mixture was stirred at 25 oC for 1 h and 
then concentrated under reduced vacuum. The crude product was purified by flash 
silica column chromatography to afford the desired product (2) (0.86 g, 87 % over 2 
steps).   
Rf (ethyl acetate/haxane):  0.50 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.36-7.18 (m, 30H, aromatics), 6.09-5.99 (m, 
1H, CH2CH=CH2), 5.33 (dd, 1H, J = 17.1, 1.2 Hz, CH=CH2), 5.22 (dd, 1H, J = 10.3, 
1.2 Hz, CH=CH2), 5.08 (d, 1H, J = 11.1 Hz), 4.97 (d, 1H, J = 11.5 Hz), 4.82 (dd, 2H, 
J = 20.4, 11.1 Hz), 4.71 (dd, 2H, J = 22.8, 6.8 Hz), 4.70 (d, 1H, J = 5.3 Hz), 4.56 (dd, 
2H, J = 11.5, 4.4 Hz), 4.43 – 4.43 (d, 1Hanomeric, J = 7.6 Hz), 4.40 (m, 3H), 4.34 (d, 
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1Hanomeric, J = 7.2 Hz),  4.48 (d, 1H, J = 11.8 Hz), 4.15 (dd, 1H, J = 12.7, 6.4 Hz), 
3.96 (d, 1H, J = 9 Hz), 3.92 (d, 1H, J = 2.7 Hz), 3.81 – 3.70 (m, 3H), 3.57 – 3.46 (m, 
3H), 3.41 – 3.34 (m, 4H), 2.39 (br, 1H, OH).        
13
 C NMR (CDCl3, 100 MHz): δ (ppm) [139.2, 139.1, 138.9, 138.7, 138.5, 138.2 
(Cq-Aryl)], 134.1 (CH2CH=CH2), 128.6 – 127.5 (m, CH-Aryl), 118.0 (CH=CH2), 
103.0 (CHanomeric), 101.7 (CHanomeric), 83.0, 82.7, 80.1, 76.5, 75.6, 75.5, 74.9, 74.8, 
73.7, 73.7, 73.3, 73.2, 72.8, 70.3, 68.4. 
 
  
HRMS-ESI (m/z): [M+Na]+Calcd for C57H62NaO11, 945.4190; Found, 945.5140. 
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Synthesis of Allyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-
hydroxy-3,6-di-O-benzyl-β-D-mannopyranoside 3. 
To a solution of allyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-3,6-di-
O-benzyl-β-D-glucopyranoside (2) (0.1 g, 0.11 mmol) in dichloromethane (5 mL) was 
added dess-martin periodinane (92 mg, 0.22 mmol). The reaction mixture was stirred 
at 35 oC for 4 h and then diluted with dichloromethane (10 mL). The diluted solution 
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was washed with sat.NaHCO3 (2 x 10 mL), H2O (1 x 10 mL), and brine (1 x 10 mL). 
The organic layer was dried with Na2SO4 and then concentrated under reduced 
vacuum.  The crude residue was dissolved in dichloromethane/MeOH (1/1) and 
cooled to 0 oC.  NaBH4 (50 mg, 1.35 mmol) was added and then the reaction mixture 
was allowed to 25 oC over 1 h.  The mixture was diluted with dichloromethane (10 
mL) and washed with H2O (1 x 10 mL), 1 % aqueous citric acid (1 x 10 mL) and 
brine (1 x 10 mL). The solvent was evaporated under reduced vacuum and dried with 
Na2SO4. The crude product was purified by flash silica column chromatography to 
afford the desired product (3) (92 m g, 92 % over 2 steps).  
Rf (ethyl acetate/haxane):  0.45 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.36-7.21 (m, 30H), 5.97-5.87 (m, 1H, 
CH2CH=CH2), 5.29 (dd, 1H, J = 16.5, 1.6 Hz, CH=CH2), 5.20 (dd, 1H, J = 10.4, 1.6 
Hz, CH=CH2), 4.97 (d, 1H, J = 11.5 Hz), 4.81 (d, 1H, J = 2 Hz), 4.78 (d, 1H, J = 2.8 
Hz), 4.75 (d, 1H, J = 10.8 Hz), 4.72-4.66(m, 4H), 4.60 (d, 1H, J = 11.5 Hz), 4.50 (d, 
1Hanomeric, J = 1.2 Hz), 4.47 (d, 1H, J = 10.8 Hz), 4.45 (d, 1Hanomeric, J = 7.9 Hz), 4.41-
4.37 (m, 3H), 4.30 (d, 1H, J = 11.6 Hz), 4.12-4.07 (m, 3H), 3.92 (d, 1H, J = 2.8 Hz), 
3.84 (dd, 1H, J = 10.8, 2.8 Hz), 3.76-3.72 (m, 2H), 3.63(t, 1H, J = 8.68 Hz), 3.56 (dd, 
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1H, J = 8.4, 3.6 Hz), 3.51-3.39 (m, 4H), 2.39 (br, 1H, OH).  
13
 C NMR (CDCl3, 100 MHz): δ (ppm) [139.1, 138.9, 138.7, 138.7, 138.6, 138.1 
(Cq-Aryl)], 134.1 (CH2CH=CH2), 128.6 – 127.6 (m, CH-Aryl), 118.0 (CH=CH2), 
103.4 (CHanomeric), 98.7 (CHanomeric), 82.8, 80.1, 79.5, 75.5, 75.4, 73.7, 73.6, 73.3, 73.2, 
72.8, 72.6, 70.0, 69.2, 68.9, 68.6,  
HRMS-ESI (m/z): [M+Na]+Calcd for C57H62NaO11, 945.4190; Found, 945.5131. 
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Synthesis of Allyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-
acetyl-3,6-di-O-benzyl-β-D-mannopyranoside 4. 
To a allyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-3,6-di-O-benzyl-β-
D-mannopyranoside (3) (80 mg, 0.09 mmol) in dichloromethane (5 mL) was added 
DMAP (6 mg, 0.05 mmol), triethylamine (0.02 mL, 0.18 mmol) and acetic anhydride 
(0.01 mL, 0.011 mmol). The reaction mixture was stirred at 25 oC for 1 h and then 
concentrated under reduced vacuum. The crude residue was dried with Na2SO4 and 
purified by flash silica column chromatography to afford the desired product (4) (76 
55 
mg, 91 %) 
Rf (ethyl acetate/haxane):  0.70 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.30-7.18 (m, 30H), 5.92-5.82 (m, 1H, 
CH2CH=CH2), 5.58 (dd, 1H, J = 2.8, <1 Hz, CHCH(OAc)CH), 5.27 (dd, 1H, J = 17.2, 
1.6 Hz, CH=CH2), 5.18 (dd, 1H, J = 10, 1.2 Hz, CH=CH2), 4.80 (d, 1H, J = 10.8 Hz), 
4.73-4.61 (m, 4H), 4.58 (d, 1H, J = 8 Hz), 4.54 (d, 1H, J = 3.6 Hz), 4.53 (d, 1Hanomeric, 
J = <1 Hz), 4.51 (d, 1Hanomeric, J = 12 Hz), 4.42-4.32 (m, 3H), 4.24 (d, 1H, J = 11.6 
Hz), 4.10 (dd, 1H, J = 13.2, 6.4 Hz), 4.98 (t, 1H, J = 9.2 Hz), 3.85 (dd, 2H, J = 11.2, 2 
Hz), 3.79-3.68 (m, 2H), 3.60-5.53 (m, 2H), 3.49-3.45 (m, 1H), 3.41-3.39 (m, 2H), 
3.33 (t, 1H, J = 6.8 Hz), 2.03 (s, 3H, OC(O)CH3).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.8 (C=O), [139.0, 138.9, 138.7, 138.6, 
138.5, 138.2 (Cq-Aryl)], 133.8 (CH2CH=CH2), 128.6 – 127.4 (m, CH-Aryl), 117.8 
(CH=CH2), 115.5, 103.0 (CHanomeric), 97.7 (CHanomeric), 82.9, 80.1, 78.5, 75.8, 75.3, 
74.8, 74.6, 73.7, 73.6, 73.4, 72.7, 71.8, 70.0, 69.3, 68.9, 68.6, 21.2(CH3). 
HRMS-ESI (m/z): [M+Na]+Calcd for C59H64NaO12, 987.4295; Found, 987.3006. 
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  Synthesis of Vinyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-
acetyl-3,6-di-O-benzyl-β-D-mannopyranoside 5. 
To a solution of allyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-
acetyl-3,6-di-O-benzyl-β-D-mannopyranoside (4) (80 mg, 0.08 mmol) in THF (3 mL) 
was added catalytic amount of (1,5-
Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (2 mg, 
0.002 mmol). The stirred solution was degassed, placed under N2 and degassed. The 
reaction mixture was placed under H2 for 5 min and degassed once more to prevent 
further reduction.  The mixture was stirred at 25 oC for 30 min under N2 and then 
concentrated under reduced vacuum. The crude residue was purified by flash silica 
column chromatography to afford the desired product (5) (75 mg, 94 %). 
Rf (ethyl acetate/haxane):  0.72 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.31-7.19 (m, 30H), 6.23 (d, 1H, J = 12.3 Hz, 
OCH=CH), 5.60 (dd, 1H, J = 2.6, <1 Hz, CHCH(OAc)CH), 5.15-5.07 (m, 1H, 
CH=CHCH3), 4.96 (d, 1H, J = 11.4 Hz), 4.82 (d, 1H, J = 10.9 Hz), 4.74-4.62 (m, 5H), 
4.71 (d, 1Hanomeric, J = <1 Hz), 4.59-4.55 (m, 2H), 4.51 (d, 1Hanomeric, J = 17.4 Hz), 
4.49-4.35 (m, 3H), 4.25 (d, 1H, J = 11.7 Hz), 4.00 (t, 1H, J = 9.1 Hz), 3.89 (d, 2H, J = 
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10.5 Hz), 3.78-3.70 (m, 2H), 3.64 (dd, 1H, J = 8.6, 3.2 Hz), 3.56-3.53 (m, 2H), 3.44-
3.40 (m, 1H), 3.35 (t, 1H, J = 6.3 Hz), 2.04 (s, 3H, OC(O)CH3), 1.54 (d, 3H, J = 6.54 
Hz, CHCH3).     
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.7 (C=O), 143.4(OCH=CH), [139.0, 
138.8, 138.7, 138.5, 138.2 (Cq-Aryl)], 128.6 – 127.4 (m, CH-Aryl), 104.9 
(CH=CHCH3) 103.0 (CHanomeric), 97.8 (CHanomeric), 82.9, 80.0, 78.2, 76.1, 75.4, 74.8, 
74.5, 73.7, 73.4, 72.8, 71.9, 69.2, 68.9, 68.1, , 21.2(CH3), 12.6 (CHCH3). 
HRMS-ESI (m/z): [M+Na]+Calcd for C59H64NaO12, 987.4295; Found, 987.3076 
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Synthesis of 2,3,4,6,-Tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-2-O-acetyl-3,6-
di-O-benzyl-α-D-mannopyranosyl trichloroacetimidate 6. 
To a vinyl O-(2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-acetyl-3,6-
di-O-benzyl-β-D-mannopyranoside (7) (75 mg, 0.08 mmol), and mercury oxide (24 
mg, 0.1 mmol) in 3 mL of acetone/H2O (10 mL /1mL)  was added a solution of 
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mercuric chloride (23 mg, 0.09 mmol) in 2 mL of  acetone/H2O (10 mL/1mL) for 1 
min. The reaction mixture was stirred at 25 oC for 3 h. The crude residue was filtered 
through celite and diluted with dichloromethane (5 mL). The organic layer was 
washed with sat. KI (1 x 5 mL), H2O (1 x 5 mL) and brine (1 x 5 mL). The solvent 
was concentrated under reduced vacuum and dried with Na2SO4. To a crude residue in 
dichloromethane (5 mL) was added Cs2CO3 (25 mg, 0.08 mmol) and followed by 
addition of trichloroacetonitrile (0.016 mL, 0.16 mmol) at 0 oC. The reaction mixture 
was stirred at 0 oC for 30 min and then concentrated under reduced vacuum and 
purified by flash silica column chromatography to afford the desired product (6) (74 
mg, 89 % over 2 steps). 
Rf (ethyl acetate/haxane):  0.80 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 8.66 (s, 1H, NH=C), 7.32-7.17 (m, 30H), 6.24 
(d, 1Hanomeric, J = 1.8 Hz), 5.43 (dd, 1H, J = 3.1, 2.8 Hz, CHCH(OAc)CH), 4.97 (d, 1H, 
J = 11.6 Hz), 4.81 (d, 1H, J = 10.8 Hz), 4.76 (d, 1H, J = 12 Hz), 4.69-4.65 (m, 3H), 
4.57 (d, 1H, J = 11.2 Hz), 4.44 (d, 1H, J = 7.6 Hz), 4.40 (d, 1H, J = 11.6 Hz), 4.38 (d, 
1H, J = 11.2 Hz), 4.28-4.22 (m, 2H), 3.95 (dd, 2H, J = 8.9, 3.2 Hz), 3.87 (dd, 1H, J = 
8.9, 7.8 Hz), 3.63-3.54 (m. 2H), 3.46-3.36 (m, 3H), 1.98 (s, 3H, OAc).      
59 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.4 (C=O), 160.1 (C=NH), [139.1, 138.9, 
138.7, 138.6, 138.5, 138.4 (Cq-Aryl)], 128.7 – 127.6 (m, CH-Aryl), 103.2 (CHanomeric), 
95.4 (CHanomeric), 82.8, 80.0, 75.5, 75.4, 74.9, 74.6, 74.0, 73.9, 73.7, 73.4, 72.9, 72.8, 
69.1, 68.5, 68.2, 21.1 (CH3).  
 
ASW Leishmania-tetrasaccharide method run 
After FSPE, the methanol elution collected in the vial was removed from the 
instrument and concentrated. Solvent was removed under reduced pressure to obtain 
the crude product (30 mg) as colorless oil. In order to obtain pure product (5) (21 mg, 
16 %) for 1H NMR, 13 C NMR and mass spectrum, further purification was performed 
using prep TLC.  
 
Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-
[2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-
mannopyranoside 11. 
Rf (ethyl acetate/haxane): 0.75 (20/80) 
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1H NMR (CDCl3, 400 MHz): δ (ppm) 7.33-7.11 (m, 30H), 5.62 (br, 2H), 5.47 (s, 1H), 
5.08 (s, 1H), 4.92 (d, 2H, J = 15.6 Hz), 4.82-4.77 (m, 3H), 4.70-4.59 (m, 6H), 4.55-
4.44 (m, 10H), 4.41-4.36 (m, 3H), 4.26 (d, 1H, J = 12 Hz), 4.21-4,18 (d, 1H, J = 12.4 
Hz), 4.15 (m, 1H), 4.05-3.98 (m, 2H), 3.92-3.82 (m, 10H), 3.78-3.69 (m, 8H), 5.57 (t, 
2H, J = 10 Hz), 3.41 (t, 2H, J = 9.2 Hz), 3.32-3.29 (m, 3H), 2.15-2.04 (m, 2H), 2.08 (s, 
3H), 1.80-1.73 (m, 2H).      
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.2 (C=O), [139.4, 139.2, 139.0, 138.9, 
138.8, 138.7, 138.6, 138.6, 138.6, 138.2, 138.2 (Cq-Aryl)], 128.5 – 127.2 (m, CH-
Aryl), [103.1, 101.2, 99.6, 98.2 95.4 (CHanomeric)], 83.0, 80.3, 79.7, 78.2, 75.4, 75.3, 
75.2, 75.0, 74.8, 74.5, 73.5, 73.4, 73.2, 72.7, 72.4, 72.3, 72.1, 72.0, 71.9, 69.7, 69.0, 
98.8, 68.5, 66.7, 63.0, 28.4, 28.3, 28.0, 21.3(CH3).   
HRMS-MALDI (m/z): [M+Na]+Calcd for C125H127F17NaO23 2341.8394; Found, 
2341.3591. 
 
- 2.5 cycles (17h 31 min 39) completed for the synthesis of Leishmania-
tetrasaccharide. 
Step Task Reagent/ Operation Operation 
Time 
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1 
 
 
 
2 
3 
4 
5 
 
6 
7 
8 
 
9 
10 
11 
12 
13 
14 
15 
Glycosylation 
 
 
 
TLC sample 
Quenching 
Evaporation 
Deacetylation 
TLC sample 
Quenching 
Evaporation 
FSPE 
preparation 
Sample loading 
Wash 
Wash 
Transfer 
Evaporation 
Transfer 
Evaporation 
2 equivalent donor  (100 µmol) in 0.5 mL 
Toluene, 
1 equivalent F-tagged acceptor (50 µmol) in 1 mL 
Toluene; 0.1 equivalent TMSOTf, rt 
30 µl of crude reaction mixture withdrawn 
0.5 ml TEA 
40 oC 
3 equivalent of NaOMe solution 
30 µl of crude reaction mixture withdrawn 
0.3 ml 0.5 M Acetic acid solution in MeOH 
50 oC 
 
0.4 ml DMF 
0.7 ml crude sample transferred to cartridge 
4.7 ml 80% methanol wash 
1.5 ml methanol wash (repeated 3 times) 
4.7 ml collected sample transferred to clean vial 
50 oC 
2 ml toluene added 
50 oC 
30 min 
 
 
 
 
45 min 
 
2 h 
 
 
45 min 
 
 
 
 
 
 
45 min 
 
45 min 
 
- HPLC trace for crude product. 
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3-(perfluorooctyl)propanyloxybutanyl-4-O-[β-D-galactopyranosyl]-2-O-[2-O-(2-
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O-α-D-mannopyranosyl)-α-D-mannopyranosyl]-α-D-mannopyranoside 11-1.. 
  To a 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-
benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D 
mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-β-D-mannopyranoside 
(11) (50 mg, 0.02 mmol) in MeOH (3 mL) was added Na (1 mg, 0.07 mmol) and 
stirred at 25 oC for 30 min. The reaction mixture was neutralized with Dowex-ion-
exchange resin and filtered through Celite pad. purified by solid phase extraction 
using fluoro flash column. The solvent was removed under reduced pressure to obtain 
deacetylated product. To a sluotion of deacetylated product in MeOH (3mL) was 
added 10 % Pd/C (50 mg). The reaction mixture was stirred at 25 oC under hydrogen 
atmosphere for 12 h. The desired (11-1) was obtained through Celite filteration 
followed by evaporation of solvent under reduced pressure in good yield (25 mg, 
96 %).   
1H NMR (CD3OD, 400 MHz): δ (ppm) [5.33 (s, 1H), 5.01 (s, 1H), 4.96 (s, 1H), 4.35 
(d, 1H, J = 8 Hz) CHanomeric)], 4.01-3.1 (m, 30H), 2.31-2.18 (m, 2H), 1.89-1.78 (m, 
2H), 1.84-1.53 (m, 4H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) [103.9, 102.9, 101.0, 98.7 (CHanomeric)], 79.2, 
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78.0, 77.6, 73.8, 73.8, 73.6, 71.8, 71.2, 70.7, 70.6, 70.5, 69.9, 69.1, 68.9, 68.0, 67.6, 
67.3, 62.1, 62.0, 61.3, 61.0, 26.4, 26.1. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C39H55F17NaO22 1221.2811; Found, 
1220.1206. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-[2,3,4,6-tetra-O-benzyl-β-D-
galactopyranosyl-]-α-D-mannopyranoside 6-1.  
To a solution of 2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-2-O-acetyl-3,6-
di-O-benzyl-α-D-mannopyranosyl trichloroacetimidate (6) (0.1 g, 0.09 mmol) and 3-
(perfluorooctyl)propanyloxybutenyl alcohol (7) (62 mg, 0.11 mmol) in dry toluene (3 
mL) was added TMSOTf (2 µL, 0.01 mmol) at 25 oC. The reaction mixture was 
stirred at room temperature for 10 min. The reaction was quenched with triethylamine 
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(0.01 mL) and concentrated under reduced pressure. The crude product was purified 
by solid phase extraction using fluoro flash column. Nonfluorous compounds were 
eluted with 5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % 
MeOH. The solvent was removed under reduced pressure to obtain the desired 
product (6-1) (0.13 g, 92 %).
Rf (ethyl acetate/haxane): 0.75 (20/80) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.30-7.17 (m, 30H), 5.75-5.65 (m, 2H), 5.29 (s, 
1H), 4.95 (d, 1H, J = 11.4 Hz), 4.82 (d, 1H, J = 11 Hz), 4.81 (d, 1H, J = <1 Hz), 4.70-
4.62 (m, 5H), 4.57-4.47 (m, 2H), 4.39 (d, 1H, J = 5.6 Hz), 4.36 (d, 1H, J = 5.2 Hz), 
4.24 (d, 1H, J = 11.8 Hz), 4.18 (d, 1H, J = 4.3 Hz), 4.10-4.06 (m, 2H), 4.01-4.00 (m, 
2H), 3.90-3.85 (m, 2H), 3.80 (d, 2H, J = 8.7 Hz), 3,72 (t, 2H, J = 8.1 Hz), 3.55 (t, 1H, 
J = 9 Hz), 3.43-3.32 (m, 5H), 2.20-2.03 (m, 2H), 1.95 (s, 3H), 1.85-1.78 (m, 2H).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.6 (C=O), [139.0, 138.9, 138.9, 138.5, 
138.5, 138.2 (Cq-Aryl)], 130.6, 128.5 – 127.3 (m, CH-Aryl), [103.1, 96.8 (CHanomeric)], 
82.0, 80.1, 76.3, 75.3, 74.8, 74.7, 73.7, 73.6, 73.3, 72.7, 72.2, 71.5, 69.6, 69.1, 69.9, 
68.9, 68.9, 66.6, 62.9, 28.2, 28.0, 21.1(CH3). 
HRMS-MALDI (m/z): [M+Na]+Calcd for C71H71F17NaO13 1478.2783; Found, 
66 
1478.2483. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-[2,3,4,6-tetra-O-benzyl-β-D-
galactopyranosyl-]-(1-4)-2-O-hydroxy-3,6-di-O-benzyl-α-D-mannopyranoside 9. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-[2,3,4,6-tetra-O-benzyl-β-D-
galactopyranosyl-]-(1-4)-2-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranoside (6-1) (0.1 
g, 0.07 mmol) in MeOH (3 mL) was added Na (1 mg, 0.07 mmol) and stirred at 25 oC 
for 30 min. The crude product was purified by solid phase extraction using fluoro 
flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and 
the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed 
under reduced pressure to obtain the desired product (10) (95 mg, 98 %). 
Rf (ethyl acetate/haxane): 0.45 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.34-7.21 (m, 30H), 5.76-5.67 (m, 2H), 4.98 
(d, 1H, J = 11.6 Hz), 4.91 (d, 1H, J = 11.6 Hz), 4.89 (d, 1H, J = <1 Hz), 4.82 (d, 1H, J 
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= 11.2 Hz), 4.75-4.69 (m, 3H), 4.63-4.50 (m, 3H), 4.43 (d, 1H , J = 10 Hz), 4.40-4.36 
(m, 2H), 4.28 (d, 1H, J = 11.6 Hz), 4.21 (dd, 1H, J = 12, 3.2 Hz), 4.13-4.07 (m, 2H), 
4.03-4.01 (m, 2H), 3.90 (d, 1H, J = 2.4 Hz), 3.79-3.69 (m, 5H), 3.58 (t, 1H, J = 8.8 
Hz), 3.46-3.37 (m, 5H), 2.21-2.08 (m, 2H), 1.85-1.79 (m, 2H).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) [139.1, 138.9, 138.8, 138.6, 138.2 (Cq-Aryl)], 
130.5, 128.6 – 127.6 (m, CH-Aryl), [103.3, 98.3 (CHanomeric)], 82.8, 80.1, 78.2, 75.4, 
74.5, 73.7, 73.7, 73.3, 73.0, 72.8, 71.4, 69.5, 68.9, 68.9, 68.7, 66.7, 62.7, 28.2. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C69H69F17NaO12 1435.4415; Found, 
1435.3106.. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-
tetra-O-benzyl-β-D-galactopyranosyl-]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl- α -D-
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mannopyranosyl]-α-D-mannopyranoside 10. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-[2,3,4,6-tetra-O-benzyl-β-D-
galactopyranosyl-]-(1-4)-2-O-hydroxy-3,6-di-O-benzyl-α-D-mannopyranoside (9) (90 
mg, 0.06 mmol) and 2-O-acetyl-3,4,6-tri-O-benzylyl-α-D-mannopyranosyl 
tricholoroacetimidate (42 mg, 0.07 mmol) in dry toluene (3 mL) was added TMSOTf 
(2 µL, 0.01 mmol) at 25 oC. The reaction mixture was stirred at 25 oC for 10 min. The 
reaction was quenched with triethylamine (0.1 mL) and concentrated under reduced 
pressure. The crude product was purified by solid phase extraction using fluoro flash 
column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the 
desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under 
reduced pressure to obtain the desired product (10) (0.11 g, 89 %). 
Rf (ethyl acetate/haxane):  0.75 (20/80) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.31-7.29 (m, 45H), 5.64-5.61 (m, 2H), 5.50 
(dd, 1H, J = 2.8, 1.6 Hz), 5.05 (d, 1H, J = 1.2 Hz), 4.89 (d, 1H, J = 11.2 Hz), 4.83-
4.77 (m, 4H), 4.68 (d, 1H, J = 11.2 Hz), 4.64-4.57 (m, 5H), 4.53 (d, 1H, J = 5.6 Hz), 
4,51-4.45 (m, 3H), 4.42 (d, 1H, J = 7.6 Hz), 4.38 (d, 1H, J = 5.2 Hz), 4.33 (d, 1H, J = 
10.8 Hz), 4.29 (d, 1H, J = 12.4 Hz), 4.21 (d, 1H, J = 12 Hz), 4.16-4.12 (m, 1H), 4.06 
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(d, 1H, J = 8.8 Hz), 4.02-4.00 (m, 1H), 3.97-3.91 (m, 4H), 3.85-3.82 (m, 3H), 3.80 (d, 
1H, J = 9.6 Hz), 3.75-3.62 (m, 6H), 3.51 (t, 1H, J = 8.8 Hz), 3.44 (d, 1H, J = 2.8 Hz), 
3.41-3.29 (m, 4H), 2.17-2.01 (m, 2H), 2.04 (s, 3H), 1.81-1.75 (m, 2H).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.0 (C=O), [139.4, 139.2, 139.1, 138.9, 
138.7, 138.7, 138.5, 138.3 (Cq-Aryl)], 130.1, 128.6 – 127.1 (m, CH-Aryl), [103.5, 
99.7, 98.2 (CHanomeric)], 83.0, 80.3, 78.7m 78.2, 75.5, 87.4, 75.2, 74.8, 74.6, 73.7, 73.1, 
72.7, 72.7, 72.2, 72.1, 72.0, 69.5, 69.2, 68.9, 68.6, 68.4, 66.8, 62.9, 28.5, 28.3, 28.1, 
21.4.  
HRMS-MALDI (m/z): [M+Na]+Calcd for C98H99F17NaO18 1909.6458; Found, 
1909.6699. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutanyl-4-O-[β-D-galactopyranosyl]-
2-O-[2-O-α-D-mannopyranosyl]-α-D-mannopyranoside 10-1. 
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To a 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-
benzyl-β-D-galactopyranosyl-]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl]-α-D-mannopyranoside (10) (50 mg, 0.03 mmol) in MeOH (3 mL) 
was added Na (1 mg, 0.07 mmol) and stirred at 25 oC for 30 min. The reaction 
mixture was neutralized with Dowex-ion-exchange resin and filtered through Celite 
pad. purified by solid phase extraction using fluoro flash column. The solvent was 
removed under reduced pressure to obtain deacetylated product. To a sluotion of 
deacetylated product in MeOH (3mL) was added 10 % Pd/C (50 mg). The reaction 
mixture was stirred at 25 oC under hydrogen atmosphere for 12 h. The desired (10-1) 
was obtained through Celite filteration followed by evaporation of solvent under 
reduced pressure in good yield (26 mg, 95 %).   
1H NMR (D2O, 400 MHz): δ (ppm) [4.95 (s, 1H), 4.87 (s, 1H), 4.29 (d, 1H, J = 8 Hz), 
CHanomeric)], 3.92-3.33 (m, 26H), 1,44-1,42 (m, 2H), 1.22-1.20 (m, 2H), 0.76-0.73 (m, 
2H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) [103.9, 102.8, 98.7 (CHanomeric)], 78.0, 77.7, 
75.7, 73.8, 73.6, 71.8, 71.8, 71.4, 71.1, 70.6, 70.5, 69.8, 69.0, 68.9, 67.6, 67.2, 61.8, 
61.2, 61.0, 60.2, 31.5, 27.6, 27.4,19.3. 13.0.  
71 
HRMS-MALDI (m/z): [M+Na]+Calcd for C33H45F17NaO17 1059.2283; Found, 
1059.3657. 
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Synthesis of 1,2,3,4,6-penta-O-acetyl-D-mannopyranoside 
To a solution of monnose (1 g, 5.6 mmol) in acetic anhydride (5 mL) was added 
catalytic amount of  iodine (50 mg, 0.2 mmol) at 25 oC. The reaction mixture was 
stirred at room temperature for 1 h. The dark brown reaction mixture was poured into 
a separatory funnel containing dichloromethane, aqueous sodium thiosulfate solution 
and crushed ice. The colorless solution from a separatory funnel was washed with 
H2O (2 x 50 mL) and sat.NaHCO3 (2 x 50 mL). It was dried with Na2SO4 and then 
concentrated under reduced vacuum to obtain the desired product 1 with quantitative 
yield. 
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Synthesis of 3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidiene)-α-D- 
mannopyranoside 
To a solution of 1,2,3,4,6-penta-O-acetyl-D-mannopyranoside (2.2 g, 5.6 mmol) in 
dichloromethane was added HBr (10 mL) for 10 min . The reaction mixture was 
stirred at 25 oC for 1 h and then checked TLC to check the completion of reaction. 
After completion of reaction, the mixture was washed with cold water three times and 
then followed by washed with saturated sodium bicarbonate solution three times. The 
neutralized solution was dried with sodium sulfate and concentrated under reduced 
pressure. The crude product was used for next step without further purification. To a 
solution of hepta-acetyl lactosyl bromide in dichloromethane was added triethylamine 
(1.6 mL, 11.2 mmol), Bu4NBr (2.0 g, 6.2 mmol) and methanol (0.2 mL, 6.7 mmol). 
The reaction mixture was stirred at 40 oC for 16 h and then washed with H2O (1 x 50 
mL). The solution was dried with Na2SO4 and then concentrated under reduced 
vacuum.  The crude produce was purified to obtain the desired product (1.56 g, 78 % 
over 3 steps) by silica column chromatography.   
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Synthesis of 3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidiene)-α-D- 
mannopyranoside 
To a solution of 3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidiene)-α-D-
mannopyranoside (1g, 2.8 mmol) in MeOH (5 mL) was added catalytic amount of Na 
(10 mg, 0.4 mmol) . The reaction mixture was stirred at 25 oC for 2 h and then 
concentrated under reduced vacuum to yield the crude deacetylated product as yellow 
foam. To a solution of deacetylated product in DMF (10 mL) was added 60 % NaH in 
mineral oil  (1.33g, 11.2 mmol), followed by addition of benzyl bromide (1.31 mL, 
11.2 mmol) and tetrabuyl ammonium iodide (31 mg, 0.08 mmol) at 0 oC. The reaction 
mixture was warmed up to 25 oC and stirred for 12 h.  The reaction mixture was 
diluted with dichloromethane (50 mL) and then washed with H2O (2 x 50mL). The 
organic layer was dried with Na2SO4 and concentrated under reduced vacuum. The 
crude product was purified by flash silica column chromatography to afford the 
desired product (1.28 g, 92 %).  
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Synthesis of 2-O-acetyl-3,4,6-tri-O-benzylyl-α-D-mannopyranosyl  
tricholoroacetimidate 8 16 
3,4,6-Tri-O-benzyl-1,2-O-(1-methoxyethylidiene)-α-D-mannopyranoside (1g, 2 
mmol) was dissolved in 80 % acetic acid (10 mL) and stirred at 25 oC for 30 min. The 
reaction mixture was diluted with dichloromethane (20 mL) and washed with H2O (3 
x 20 mL) followed by with sat.NaHCO3 (1 x 20 mL). The solution was dried with 
Na2SO4 and concentrated under reduced pressure. To a crude residue in 
dichloromethane was added Cs2CO3 (0.32 g, 1 mmol) and followed by addition of 
trichloroacetonitrile (0.4 mL, 4 mmol) at 0 oC. The reaction mixture was stirred at 0 
oC for 30 min and then concentrated under reduced pressure. The crude residue was 
dried with Na2SO4 and purified by flash silica column chromatography to afford the 
desired product (8) (1.15 g, 92 %). 
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Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-tri-O-benzyl-
α-D-mannopyranoside 12.21 
To a solution of 2-O-acetyl-3,4,6-tri-O-benzylyl-α-D-mannopyranosyl 
tricholoroacetimidate (8) (0.3 g, 0.47 mmol) and 3-
(perfluorooctyl)propanyloxybutenyl alcohol (2) (0.13 g, 0.24 mmol) in dry 
dichloroethane (5 mL) was added TMSOTf (8.5 µL, 0.05 mmol) at 25 oC. The 
reaction mixture was stirred at room temperature for 30 min. The reaction was 
quenched with triethylamine (0.5 mL) and concentrated under reduced pressure. The 
crude product was purified by solid phase extraction using fluoro flash column. 
Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired 
product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced 
pressure to obtain the desired product (12) (0.20 g, 84 %).  
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Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-
acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)- α-D-mannopyranoside 1321. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-O-benzyl- 
α-D-mannopyranoside (12) (0.2 g, 0.2 mmol) in MeOH (5 mL) was added Na (4 mg, 
0.2 mmol) and stirred at 25 oC for 30 min. The crude product was purified by solid 
phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 
5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % MeOH. 
The solvent was removed under reduced pressure to obtain the desired product (0.18 g, 
94 %). To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-α-D-
mannopyranoside (0.18g, 0.19 mmol) and of 2-O-acetyl-3,4,6-tri-O-benzylyl-α-D-
mannopyranosyl tricholoroacetimidate (0.13 g, 0.21 mmol) in toluene (5 mL) was 
added TMSOTf (2 µL, 0.11 mmol) at 25 oC. The reaction mixture was stirred at 25 oC 
for 10 min. The reaction was quenched with triethylamine (30 µL) and concentrated 
under reduced pressure. The crude product was purified by solid phase extraction 
using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % 
MeOH/H2O and the desired product was eluted by 5 mL 100 % MeOH. The solvent 
was removed under reduced pressure to obtain the desired product (13) (0.23 g, 86 %). 
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Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-2-O-[2-O-(2-
O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl]- α-D-mannopyranoside 14.21 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-
acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (13) (0.2g, 
0.14 mmol) in MeOH (5 mL) was added Na (3 mg, 0.14 mmol) and stirred at 25 oC 
for 30 min. The crude product was purified by solid phase extraction using fluoro 
flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and 
the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed 
under reduced pressure to obtain the desired product (0.18 g, 92 %) 
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To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-α-D-
mannopyranosyl-(1-2)-3,4,6-O-benzyl- α-D-mannopyranoside (0.18 g, 0.13 mmol) 
and 2-O-acetyl-3,4,6-tri-O-benzylyl-α-D-mannopyranosyl tricholoroacetimidate (91 
mg, 0.14 mmol) in toluene (5 mL) was added TMSOTf (2 µL, 0.11 mmol) at 25 oC. 
The reaction mixture was stirred at 25 oC for 30 min. The reaction was quenched with 
triethylamine (30 µL) and concentrated under reduced pressure. The crude product 
was purified by solid phase extraction using fluoro flash column. Nonfluorous 
compounds were eluted with 5 mL 80 % MeOH/H2O and the desired product was 
eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to 
obtain the desired product (14) (0.21 g, 86 %). 
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Synthesis of 3-(perfluorooctyl)propanyloxybutanyl--2-O-(2-O-α-D- 
mannopyranosyl)-α-D-mannopyranoside 13-1. 
79 
To a 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)- α-D-mannopyranoside (13) (50 mg, 0.03 
mmol) in MeOH (3 mL) was added Na (1 mg, 0.07 mmol) and stirred at 25 oC for 30 
min. The reaction mixture was neutralized with Dowex-ion-exchange resin and 
filtered through Celite pad. purified by solid phase extraction using fluoro flash 
column. The solvent was removed under reduced pressure to obtain deacetylated 
product. To a sluotion of deacetylated product in MeOH (3mL) was added 10 % Pd/C 
(50 mg). The reaction mixture was stirred at 25 oC under hydrogen atmosphere for 12 
h. The desired (13-1) was obtained through Celite filteration followed by evaporation 
of solvent under reduced pressure in good yield (29 mg, 95 %).   
1H NMR (CD3OD, 400 MHz): δ (ppm) [5.06 (s, 1H), 4.96 (s, 1H) CHanomeric)], 3.81-
3.31 (m, 22H), 2.30-2.18 (m, 2H), 1.87-1.76 (m, 2H), 1.68-1.60 (m, 2H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) [103.0, 98.7 (CHanomeric)], 79.5, 73.8, 73.4, 
71.2, 71.0, 70.6, 68.9, 67.8, 67.6, 67.1, 61.9, 61.8, 60.2, 27.8, 27.6, 26.4, 26.1. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C27H35F17NaO12 897.1289; Found, 
897.1755. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutanyl-2-O-[2-O-(2-O-α-D- 
mannopyranosyl)-α-D-mannopyranosyl]-α-D-mannopyranoside 14-1.  
To a 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]- 
α-D-mannopyranoside (14) (50 mg, 0.03 mmol) in MeOH (3 mL) was added Na (1 
mg, 0.07 mmol) and stirred at 25 oC for 30 min. The reaction mixture was neutralized 
with Dowex-ion-exchange resin and filtered through Celite pad. purified by solid 
phase extraction using fluoro flash column. The solvent was removed under reduced 
pressure to obtain deacetylated product. To a sluotion of deacetylated product in 
MeOH (3mL) was added 10 % Pd/C (50 mg). The reaction mixture was stirred at 25 
oC under hydrogen atmosphere for 12 h. The desired (14-1) was obtained through 
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Celite filteration followed by evaporation of solvent under reduced pressure in good 
yield (26 mg, 93 %).   
1H NMR (CD3OD, 400 MHz): δ (ppm) [5.27 (s, 1H), 5.06 (s, 1H), 4.97 (s, 1H) 
CHanomeric)], 4.02-3.03 (m, 29H), 2.31-2.17 (m, 1H), 1.87-1.76 (m, 2H), 1.58-1.51 (m, 
1H), 1.43-1.35(m, 1H).  
13
 C NMR (CD3OD, 100 MHz): δ (ppm) [102.9, 101.3, 98.6 (CHanomeric)], 79.7, 79.1, 
73.8, 71.2, 71.0, 70.7, 70.5, 68.9, 68.0, 67.8, 67.6, 67.1, 62.1, 62.0, 61.8, 27.6, 27.4, 
26.4, 26.1.  
HRMS-MALDI (m/z): [M+Na]+Calcd for C33H45F17NaO17 1059.2283; Found, 
1059.1600. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutanyl-β-D-galactopyranoside 1522. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-2,3,4,6-tetra-O-acetyl-β-D-
galactopyranoside22 (50 mg, 0.06 mmol) in MeOH (3 mL) was added Na (2 mg, 0.14 
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mmol) and stirred at 25 oC for 2 h. The reaction mixture was neutralized with Dowex-
ion-exchange resin. The desired (15) was obtained through Celite filteration followed 
by evaporation of solvent under reduced pressure in good yield (39 mg, 97 %).  
1H NMR (CD3OD, 400 MHz): δ (ppm) 4.21 (s, 1H, J = 7.6 Hz CHanomeric), 3.92-3.45 
(m, 12H), 2.31-2.18 (m, 2H), 1.87-1.80 (m, 2H), 1.72-1.63 (m, 4H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) 103.7 (CHanomeric), 75.4, 73.8, 71.3, 70.5, 
69.2, 69.0, 68.8, 61.2, 26.3, 26.1.  
HRMS-ESI (m/z): [M+Na]+Calcd for C21H25F17NaO7 735.1227; Found, 735.1095. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutanyl-4-O-β-D-galactopyranosyl)-β-
D-glucopyranoside 16.22 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-4-O-(2,3,4,6-tetra-O-acetyl-
β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β-D-glucopyranoside22 (50 mg, 0.04 mmol) 
in MeOH (3 mL) was added Na (3 mg, 0.21 mmol) and stirred at 25 oC for 4 h. The 
83 
reaction mixture was neutralized with Dowex-ion-exchange resin. The desired (16) 
was obtained through Celite filteration followed by evaporation of solvent under 
reduced pressure in good yield (36 mg, 96 %).  
1H NMR (CD3OD, 400 MHz): δ (ppm) [4.77 (d, 1H, J = 3.6 Hz), 4.34 (s, 1H, J = 7.6 
Hz) CHanomeric], 3.76-3.69 (m, 9H), 3.51-3.48 (m, 11H), 2.32-2.18 (m, 2H), 1.88-1.81 
(m, 2H), 1.72-1.63 (m, 2H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) [103.8, 98.7 (CHanomeric)], 79.7, 75.9, 73.6, 
72.3, 72.3, 72.0, 71.3, 70.9, 70.5, 69.1, 68.9, 67.7, 61.3, 60.6, 26.4, 26.1.  
HRMS-ESI (m/z): [M+Na]+Calcd for C27H35F17NaO12 897.1755; Found, 897.1510. 
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CHAPTER 4 
Development of automated synthesis and screening of phosphate-linked 
Leishmania-associated carbohydrates 
Eun-Ho Song and Nicola L. Pohl 
 
Introduction 
Since fluorous-based automation platform became a reliable tool for automated 
synthesis of oligosaccharides,1automated synthesis of phosphoglycans becomes a 
challenge due to its unique phosphate-linked structure and function. Unlike 
glycosylation and deacetylation for the construction of oligosaccharide in an 
automation platform, forming phosphate-linkage requires three steps; coupling, 
oxidation and deprotection.  
In order to extend the versatility of fluorous-based automation platform, we 
examined its application for the synthesis of phophoglycan repeats in Leishmania 
surface glycolipid, lipophosphoglycan (LPG).  
The role of lipophosphoglycan (LPG) in parasite virulence has been intensively 
reported in the field of parasite biology due to its importance during macrophage 
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infection.2 Nevertheless, their role in parasite virulence is controversial issue.3, 4 But, 
now there is no longer any doubt that Leishmania cannot survive in sand flies and 
macrophages without LPG.5, 6  
As shown in figure 1, the structure of LPG has been characterized by mass 
spectrometry and NMR spectroscopy.7, 8 Phsphoglycan repeats are the most abundant 
Leishmania-surface molecules in LPG due to difference in the length distribution 
among three domains. Moreover, each species has unique structure of phosphoglycan 
repeats in LPG. For example, L. donovani PGs consists of linear [-6Galp-β1,4-
Manp-α1-phosphate]navg.=12 repeats and L. major PGs consists of branched [6-(Gal-
β1,3)-Galp-β1,4- Manp-α1-phosphate] navg.=27 repeats.  
Although there have been several studies made on the identification of 
phosphoglycan repeats functions such as part of epitopes for recognition by 
macrophage receptors and playing a key role in parasite survival early in the sand fly,9 
these studies were not performed with pure phosphoglycan repeats due to the 
impossibility to obtain pure phosphoglycan repeats from LPG. Thus, we can only 
assume that PGs might play a crucial role in parasite virulence. While there has been 
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increasing interest in the study of PGs function, specific study has been restricted due 
to the limited access to pure synthesized PGs. 
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 Figure 1. Structure of the lipophosphoglycan of Leishmania donovani. 
 
Interestingly, capping structures are also linked to phosphoglycan repeats through 
phosphate. Like capping structure, phosphate groups might serve as distinct epitopes 
and profoundly affect antibody binding. Given this thought, it can be hypothesized 
that phosphate-linkages are involved in synergistic antibody bindings. Fluorous-based 
microarray10 can also be used to demonstrate the effect of phosphate-linkages in 
antibody bindings.  
 In this regard, rapid and efficient chemical synthesis for the construction of 
Leishmania phosphoglycan repeats and phosphate-linked capping structures has been 
prerequisite due to its biological interests for unveiling PGs and phosphate specific 
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functions in parasite virulence and their potential role in immunomodulation for 
vaccine development.   
Several attempts for both chemical synthesis of L. donovani PGs11-13 and L. major 
PGs14-16 have been made through either using monosaccharide building blocks 
(galactose and mannose) with multiple steps for protection, deprotection, and 
glycosylation or disaccharide building block. In the study which used disaccharide 
building block, iterative synthesis of PGs has been achieved by solid-phase11, but the 
use of automation platform for synthesis of PGs has never been reported. Unlike 
oligonucleotide and peptides synthesis via a synthesizer, phosphate-linked 
oligosaccharides such as phosphoglycan have never been synthesized by using an 
automation platform due to the difficulty of managing anomeric stereochemistry and 
instability of the anomeric phosphodiester. In order to overcome these limitations, we 
focused on the development of synthetic methods under H-phosphonate chemistry17 
and it led to the discovery of an efficient method for the synthesis of phosphate-linked 
oligosaccharides. 
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Herein, we reported the first fluorous-based automated synthesis of linear 
phosphoglycan repeats for L. donovani and phosphate-linked Leishmania-associated 
capping structures through a H-phosphonate strategy.  
 
Results and discussion 
Synthesis of L. donovani phosphoglycan building block 
A known intermediate orthoester18 served as starting material for the synthesis of 
phosphoglycan donor (Scheme 1). According to the conditions previously developed 
by Ruhela et al.11, regioselective silylation of 6-position of galactose on orthester was 
performed by using Bu3Sn/MeOH and TBDPSCl in reasonably high yield (80 % 3 
steps). Subsequence benzylation gave the benzylated orthoester 1 in 85 % respectively. 
Lewis acid-mediated allylation by using allyl alcohol and TfOH was followed by 
reaction with NaOMe to yield 2-O-unprotected disaccharide 2 in high yield (82% over 
2 steps). With 2-O-unprotected disaccharide 2, conversion of β-glucoside 2 to α-
mannoside 3 was successively accomplished under a two-step oxidation-reduction 
process by using Dess-Martin periodate and subsequence reduction with NaBH4. 
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Further protection of 2-O-unprotected disaccharide 3 with Piv-Cl gave fully protected 
disaccharide 5 in 91 % respectively.  
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Scheme 1. Synthesis of L. donovani phosphoglycan building block 
 
Iridium-catalyzed isomerization19 of allyl ether 4 was carried out in order to give 
trans-propenyl ether 5 and then free anomeric-OH was introduced under non-acidic 
conditions20 using HgO/HgCl2 to furnish pure α-hemiacetal product in 91 % 
respectively after removal of β-hemiacetal product through silica column purification.  
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Scheme 2. Synthesis of L. donovani phosphoglycan donor 
 
PCl3/imidazole reagent21 has been widely used as phosphonylating agent for 
formation of H-phosphonate monoester in carbohydrate due to its high reactivity. 
However, phsphonylation using PCl3/imidazole requires not only laborious 
experimental procedure but also very careful handling of PCl3 which is classified very 
toxic and corrosive by EPA.  
Instead of using PCl3/imidazole, phosphorous acid/Piv-Cl system enabled us to 
accomplish phsphonylation of 6 in good yield (83 %) though pivaloyl chloride-
mediated coupling reaction22. H-phposphonate donor 6 was confirmed by unique large 
coupling constant of 31P-1H (doublet, JHP= 632.4 Hz in 1H NMR), 31P NMR (1.31 
ppm) and HRMS ([M+Na]+Calcd 1177.4898; Found 1177.0978 ). 
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Scheme 3. Synthesis of L. donovani phosphoglycan 
 
  In order to optimize conditions for the synthesis of phosphodiester prior to run 
synthesizer, another pivaloyl chloride mediated coupling reaction for the introduction 
of fluorous-tag was followed by oxidation23 with iodine in aqueous pyridine to furnish 
fluorous-tagged β-D-galactopyranosyl-(1→4)-α-D-mannopyranosyl 
phosphodiester 7 in 87 % yield.  
 
Automated synthesis of L. donovani phosphoglycan repeats. 
   The automated synthesis of L. donovani phosphoglycan repeats was designed to 
carry out 2 and 2/3 cycles including 3 x coupling for the enlogation of disaccharide 
repeat, 3 x oxidation for the transformation of phosphite to phosphate, 2 x desilylation 
for the deprotection of TBDPS group and 5 x FSPE for the purification of crude 
product (Scheme 4). Each reaction cycle was programmed to use only 2 equivalent of 
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H-phposphonate donor 6 PIv-Cl, iodine and TBAF. As expected, the use of TLC in 
monitoring reactions enabled us to confirm the completion of each step of the reaction 
during running synthesizer. After 2.5 automation cycles, 23 mg of crude hexa-
phosphoglycan repeats with high purity was obtained from automation platform 
without further purification. With conventional purification with prep TLC, 19 mg of 
pure product was provided in overall 10 % yield (75 % per step).   
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Scheme 4. Automated synthesis of L. donovani phosphoglycan repeats 
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Synthesis of phosphate-linked Leishmania-associated capping structures 
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Scheme 5. Synthesis of H-phosphonate fluorous-tagged alcohol. 
 
α-Hemiacetal products of Leishmania-associated capping structures were prepared 
as reported in previous study.24 Pivaloyl chloride mediated coupling reaction 
underwent efficiently to produce H-phosphonate fluorous-tagged alcohol 9 in good 
yields (82 %). Subsequent coupling reaction of H-phosphonate fluorous-tagged 
alcohol using phosphorous acid/Piv-Cl with α-hemiacetal intermediates followed by 
oxidation with iodine in aqueous pyridine resulted in the production of fluorous-
tagged Leishmania capping phosphodiesters in good yields (81 % ~ 89 %).  
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Figure 2. Phosphate-linked Leishmania-associated capping structures. 
 
Conclusion 
In conclusion, the first automated synthesis of L. donovani phosphoglycan repeats 
demonstrated that phosphate-linked oligosaccharide can be readily available in the 
97 
newly developed fluorous-based automation platform within a short period, with low 
cost and less laborious work. More importantly, the synthesis of phosphate-linked 
Leishmania-associated capping structures for L. donovani and L. major has led to 
advances in understanding of the role of phosphate in antibody bindings. The study 
for the detection of glycolipid specific antibodies in serum from Leishmania infected 
animals using phosphate-linked Leishmania-associated capping structures will be 
exploited.  
 
Experimental section 
General methods 
Solvents were reagent grade and in most cases dried prior to use. All other 
commercially available reagents were used as received unless otherwise noted. The 
organic extracts were dried over anhydrous MgSO4. Tetrahydrofuran (THF) was 
distilled from lithium aluminum hydride (LiAlH4) prior to use. Methylene chloride 
(CH2Cl2), and triethylamine (Et3N) were distilled from calcium hydride. Diethyl ether 
(Et2O) was distilled from sodium-benzophenone ketyl.  
  
1H and 13C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-
98 
400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an 
Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems 
QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per 
million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are 
reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.   
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Synthesis of 2,3,4-Tri-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D- 
galactopyranosyl-(1-4)-3,6-di-O-benzyl-1,2-O-(1-methoxyethylidiene)-β-D-
glucopyranoside 1. 
  To a solution of 2,3,4,6,-tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-3,6-di-O-
acetyl-1,2-O-(1-methoxyethylidiene)-β-D-glucopyranoside18 (2 g, 3.1 mmol) in 
MeOH (10 mL) was added catalytic amount of Na (140 mg, 6.2 mmol). The reaction 
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mixture was stirred at 25 oC for 3 h and then was filtered through a Celite pad. The 
crude deacetylated product as yellow foam was obtained after concentration of 
reaction mixture under reduced vacuum. To a solution of deacetylated product in 
anhydrous MeOH (20 mL) was added Bu2SnO (0.77 g, 3.1 mmol) and then the 
reaction mixture was heated to reflux for 4 h followed by evaporation of solvent. To a 
solution of a dibutyltin compound in anhydrous THF was added TBDPSCl (0.72 mL, 
3.1 mL) and then the reaction mixture was stirred at 25 oC for 48 h. The solvent was 
concentrated under reduced vacuum. The crude product was purified by flash silica 
column chromatography (3 % MeOH in DCM) to afford the desired product 2,3,4-tri-
O-hydroxy-6-O-(tert-butyldiphenylsilyl)-β-D-galactopyranosyl-(1-4)-3,6-di-O-
hydroxy-β-D-glucopyranoside (1.88 g, 80 % over 2 steps). To a solution of TBDPS-
protected product (1.88 g, 3.0 mmol) in DMF (10 mL) was added 60 % NaH (0.99 g, 
30 mmol), followed by addition of benzyl bromide (3.5 mL, 30 mmol) and 
tetrabuylammonium iodide (1.1 g, 3.0 mmol) at 0 oC. The reaction mixture was 
warmed up to 25 oC and stirred for 12 h. The reaction mixture was diluted with 
dichloromethane (20 mL) and then washed with H2O (2 x 20mL). The organic layer 
was dried with Na2SO4 and concentrated under reduced vacuum. The crude product 
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was purified by flash silica column chromatography to afford the desired product 1 
(2.73 g, 85 % over 2 steps).  
Rf (ethyl acetate/haxane):  0.83 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.54-7.07 (m, 35H), 5.67 (d, 1H, J = 5.2 Hz), 
5.00 (d, 1H, J = 9.6 Hz), 4.85-4.77 (m, 4H), 4.63 (d, 1H, J = 16 Hz), 4.59 (d, 1H, J = 
15.2 Hz), 4.55 (d, 1H, J = 12.8 Hz), 4.40 (t, 1H, J = 11.2 Hz), 4.27 (m, 1H), 4.18 (d, 
1H, J = 8 Hz), 4.03 (br, 1H), 3.95-3.86 (m, 3H), 3.75-3.58 (m, 5H), 3.72 (dd, 1H, J = 
8.8, 2.4 Hz), 3.28-3.25 (m, 1H), 3.22 (s, 3H), 1.54 (s, 3H), 1,02 (s, 9H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) [139.3, 139.1, 138.9, 138.7, 138.3 (Cq-Aryl)], 
[130.2-127.8 (m, CH-Aryl)] 135.8, 135.7, [105.6, 97.8 (CHanomeric)], 82.3, 79.7, 75.3, 
74.9, 74.3, 73.4, 72.1, 70.3, 69.4, 62.0, 51.2, 27.3, 20.6, 19.5. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C66H74NaO12Si, 1109.4847; Found, 
1109.6400. 
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Synthesis of Allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)-3,6-di-O-benzyl-2-O-hydroxy-β-D-glucopyranoside 2. 
A solution of 2,3,4-Tri-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl-(1-4)-3,6-di-O-benzyl-1,2-O-(1-methoxyethylidiene)-β-D-
glucopyranoside 1 (2 g, 1.8 mmol) and ally alcohol (1.25 mL, 18 mmol) in 
dichloromethane (10 mL) was cooled to  – 40 oC  and TfOH (10 µL, 0.12 mmol) 
was added dropwise over 10 min. The reaction mixture was stirred at – 40 oC for 30 
min and allowed to 25 oC for 1 h followed by addition of triethylamine to neutralize a 
solution. The crude product was obtained after concentration of solvent under reduced 
vacuum. To a crude product in MeOH was added Na (41 mg, 1.8 mmol). The reaction 
mixture was stirred at 25 oC for 1 h and then concentrated under reduced vacuum.  
The crude product was purified by flash silica column chromatography to afford the 
desired product 2 (1.62 g, 82 % over 2 steps).   
Rf (ethyl acetate/haxane):  0.50 (25/75) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.56-6.98 (m, 35H), 5.98-5.88 (m, 1H), 5.32 
(dd, 1H, J = 17.2, 1.6 Hz), 5.21 (dd, 1H, J = 10.4, 1.2 Hz), 5.07 (d, 1H, J = 11.2 Hz), 
5.02 (d, 1H, J = 10.8 Hz), 4.81-4.73 (m, 3H), 4.60-4.54 (m, 3H), 4.39-4.30 (m, 4H), 
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4.13 (dd, 1H, J = 12.8, 6.4 Hz), 4.01 (d, 1H, J = 2.8 Hz), 3.88 (t, 1H, J = 9.2 Hz), 3.86 
(d, 1H, J = 12 Hz), 3.81-3.64 (m, 4H), 3.446-3.44 (m, 1H), 3.41-3.33 (m, 3H), 3.24 
(dd, 1H, J = 9.2, 5.2 Hz), 1.03 (s, 9H).  
13
 C NMR (CDCl3, 100 MHz): δ (ppm) [139.2, 138.9, 138.7, 138.6, 138.4 (Cq-Aryl)], 
135.5, 134.0, 133.2, [129.8-127.1 (m, CH-Aryl)], 117.8, [102.7, 101.5 (CHanomeric)], 
82.8, 82.4, 80.2, 77.4, 76.8, 76.1, 75.5, 75.3, 74.9, 74.3, 73.7, 73.2, 70.0, 68.1, 61.3, 
27.0, 19.2. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C66H74NaO11Si, 1093.4898; Found, 
1093.4898. 
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Synthesis of Allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)-3,6-di-O-benzyl-2-O-hydroxy-β-D-mannopyranoside 3. 
To a solution of allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)-3,6-di-O-benzyl-2-O-hydroxy-β-D-glucopyranoside 2 (1.5 g, 
0.14 mmol) in dichloromethane (10 mL) was added dess-martin periodinane (1.2 g, 
0.28 mmol). The reaction mixture was stirred at 35 oC for 4 h and then diluted with 
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dichloromethane (10 mL). The diluted solution was washed with sat.NaHCO3 (2 x 5 
mL), H2O (1 x 5 mL), and brine (1 x 5 mL). The organic layer was dried with Na2SO4 
and then concentrated under reduced vacuum. The crude residue was dissolved in 
dichloromethane/MeOH (1/1) and cooled to 0 oC.  NaBH4 (0.11 mg, 0.28 mmol) was 
added and then the reaction mixture was allowed to 25 oC over 1 h. The mixture was 
diluted with dichloromethane (10 mL) and washed with H2O (1 x 5 mL), 1 % aqueous 
citric acid (1 x 5 mL) and brine (1 x 5 mL). The solvent was evaporated under 
reduced vacuum and dried with Na2SO4. The crude product was purified by flash 
silica column chromatography to afford the desired product 3 (1.29 g, 86 % over 2 
steps).  
Rf (ethyl acetate/haxane): 0.47 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.57-7.06 (m, 35H), 5.94-5.84 (m, 1H), 5.27 
(dd, 1H, J = 17.2, 1.6 Hz), 5.18 (dd, 1H, J = 10.4, 1.2 Hz), 5.05 (d, 1H, J = 11.2 Hz), 
4.79-4.74 (m, 4H), 4.70 (d, 1H, J = 12 Hz), 4.63 (d, 1H, J = 15.6 Hz), 4.59 (d, 1H, J = 
12 v), 4.51 (d, 1H, J = 12 v), 4.45 (d, 1Hanomeric, J = 0.8 Hz), 4.40-4.35 (m, 2H), 4.39 
(d, 1Hanomeric, J = 8 Hz), 4.08-3.98 (m, 4H), 3.86 (t, 1H, J = 9.2 Hz), 3.79-3.71 (m, 4H), 
3.48-3.40 (m, 3H), 3.29 (dd, 1H, J = 8.8, 5.2 Hz), 1.01 (s, 9H). 
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13
 C NMR (CDCl3, 100 MHz): δ (ppm) [139.2, 138.8, 138.6, 138.5, 138.4 (Cq-Aryl)], 
135.5, 133.9, 133.2, [129.8-127.2 (m, CH-Aryl)], 117.7, [103.1, 98.5 (CHanomeric)], 
82.5, 80.1, 79.1, 75.4, 75.2, 74.6, 74.3, 74.2, 73.7, 73.2, 72.8, 72.6, 69.8, 68.9, 27.0, 
19.2. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C66H74NaO11Si, 1093.4898; Found, 
1093.4898. 
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Synthesis of Allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)- 2-O-trimetylacetyl-3,6-di-O-benzyl-β-D- 
mannopyranoside 4. 
To a allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)-3,6-di-O-benzyl-2-O-hydroxy-β-D-mannopyranoside 3 (1 g, 
0.9 mmol) in dichloromethane (5 mL) was added DMAP (57 mg, 0.5 mmol), 
triethylamine (0.62 mL, 0.18 mmol) and trimethyl acetylchloride (0.23 mL, 0.18 
mmol). The reaction mixture was stirred at 25 oC for 1 h and then concentrated under 
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reduced vacuum. The crude residue was purified by flash silica column 
chromatography to afford the desired product 4 (1.04 mg, 96 %) 
Rf (ethyl acetate/haxane): 0.65 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.54-7.00 (m, 35H), 5.89-5.79 (m, 1H), 5.46 
(d, 1H, J = 3.2 Hz), 5.25 (dd, 1H, J = 17.2, 1.6 Hz), 5.15 (dd, 1H, J = 10.4, 1.2 Hz), 
5.05 (11.6), 4.78-4.69 (m, 4H), 4.60 (d, 2H, J = 12 Hz), 4.54 (d, 2H, J = 9.6 Hz), 4.48 
(d, 1H, J = 5.2 Hz), 4.45 (d, 1H, J = 12 Hz), 4.32-4.27 (m, 1H), 4.05-3.98 (m, 2H), 
3.95 (d, 1H, J = 2.4 Hz), 3.84-3.80 (m, 3H), 3.74 (dd, 1H, J = 9.6, 8 Hz), 3.55-3.50 (m, 
2H), 3.46-3.45 (m, 1H), 3.42 (dd, 1H, J = 9.6, 2.8 Hz), 3.22 (dd, 1H, J = 8.8, 5.2 Hz), 
1.05 (s, 9H), 1.01 (s, 9H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 177.7 (C=O), [139.2, 138.9, 138.7, 138.6, 
138.4 (Cq-Aryl)], 135.5, 133.9, 133.2, [129.8-127.0 (m, CH-Aryl)], 117.7, [102.7, 
97.6 (CHanomeric)], 82.6, 80.1, 77.7, 75.6, 75.1, 74.6, 74.2, 73.9, 73.6, 73.0, 72.9, 71.5, 
69.5, 68.8, 68.5, 61.5, 38.9, 27.1, 27.0, 19.2. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C71H82NaO12Si, 1178.4788; Found, 
1178.4167. 
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Synthesis of Vinyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)- 2-O-trimetylacetyl-3,6-di-O-benzyl-β-D- 
mannopyranoside 5. 
To a allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)- 2-O-trimetylacetyl-3,6-di-O-benzyl-β-D-mannopyranoside 4 
(1 g, 0.09 mmol) in THF (10 mL) was added catalytic amount of (1,5-
Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (10 mg, 
0.01 mmol). The stirred solution was degassed, placed under N2 and degassed. The 
reaction mixture was placed under H2 for 5 min and degassed once more to prevent 
further reduction.  The mixture was stirred at 25 oC for 30 min under N2 and then 
concentrated under reduced vacuum. The crude residue was purified by flash silica 
column chromatography to afford the desired product 5 (0.93 g, 93 %). 
Rf (ethyl acetate/haxane):  0.68 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.54-7.00 (m, 35H), 6.18 (dd, 1H, J = 12.4, 
1.6 Hz), 5.46 (d, 1H, J = 2.4 Hz), 5.04-4.99 (m ,1H), 5.02 (d, 1H, J = 11.6 Hz), 4.76-
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4.67 (m, 6H), 4.58-4.40 (m, 7H), 3.97 (t, 1H, J = 9.2 Hz), 3.93 (d, 1H, J = 2.4), 3.81-
3.77 (m, 4H), 3.73 (dd, 1H, J = 9.6, 8 Hz), 3.54-3.48 (m, 4H), 3.42 (dd, 1H, J = 9.6, 
2.8 Hz), 3.21 (dd, 1H, J = 8.8, 4.8 Hz), 1.50 (dd, 3H, J = 6.8, 1.2 Hz), 1.03 (s, 9H), 
0.99 (s, 9H).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 177.8 (C=O), 143.8, [139.5, 139.2, 139.0, 
138.9, 138.7 (Cq-Aryl)], 135.9, 133.5, 133.5, [128.8-127.4 (m, CH-Aryl)], 104.4, 
[103.1, 98.0 (CHanomeric)], 82.6, 80.1, 77.8, 76.2, 75.5, 75.0, 74.6, 74.1, 74.0, 73.3, 
73.3, 72.0, 69.0, 68.5, 61.8, 39.3, 27.5, 27.4, 19.6, 12.8.. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C71H82NaO12Si, 1178.4788; Found, 
1178.8628. 
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Synthesis of Triethylammonium (2,3,4-tetra-O-benzyl-6-O-(tert- 
butyldiphenylsilyl)-β-D-galactopyranosyl)-(1-4)- 2-O-trimetylacetyl-3,6-di-O- 
benzyl-β-D-mannopyranosyl hydrogen phosphonate 6. 
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To a vinyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)- 2-O-trimetylacetyl-3,6-di-O-benzyl-β-D-mannopyranoside 5 
(0.9 g, 0.8 mmol), and mercury oxide (0.24 g, 0.1 mmol) in 10 mL of acetone/H2O 
(10/1)  was added a solution of mercuric chloride (0.23 g, 0.9 mmol) in 5 mL of  
acetone/H2O (10/1) for 1 min. The reaction mixture was stirred at 25 oC for 3 h. The 
crude residue was filtered through celite and diluted with dichloromethane (5 mL). 
The organic layer was washed with sat. KI (1 x 5 mL), H2O (1 x 5 mL) and brine (1 x 
5 mL). The solvent was dried with Na2SO4 and concentrated under reduced vacuum. 
The crude residue was purified by flash silica column chromatography to afford the 
hydrolyzed product (0.79 g, 91 %). Hydrolyzed compound (0.7 g, 0.6 mmol) and 
phosphonic acid (57 mg, 0.7 mmol) were coevaporated with pyridine and dried under 
high vacuume for 30 min. To a solution of this mixture in pyridine (5 mL) was added 
a solution of pivaloyl chloride (0.085 mL, 0.7 mmol) in pyridine (2 mL) and then the 
mixture was stirred at 25 oC for 30 min under nitrogen gas environment. Prydine was 
removed under reduced vacuum and the crude product was purified by flash silica 
column chromatography (with triethylamine) to afford the desired product 6 (0.86 g, 
83 %). 
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Rf (10 % MeOH in DCM): 0.5. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.51-7.15 (m, 35H), 6.98 (d, 1H, JHP = 685 
Hz), 5.53 (d, 1H, J = 8.8 Hz), 5.30 (s, 1H), 5.06 (d, 1H, J = 11.2 Hz), 4.80-4.70 (m, 
5H), 4.66-4.56 (m, 4H), 4.46 (d, 1H, J = 11.2 Hz), 4.38-4.35 (m, 2H), 4.14 (t, 1H, J = 
9.6 Hz), 4.02-3.90 (m, 5H), 3.80-3.70 (m, 3H), 3.66 (d, 1H, J = 9.6 Hz), 3.44 (dd, 1H, 
J = 9.2 Hz), 3.38 (dd, 1H, J = 9.6, 2.4 Hz), 0.99 (s, 9H), 0.93 (s, 9H).  
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 177.5 (C=O), [139.4, 139.2, 139.0, 138.0, 
138.9 (Cq-Aryl)], 135.6, 133.4, 133.4, [129.9-126.8 (m, CH-Aryl)], [103.3, 93.5 
(CHanomeric)], 82.7, 80.2, 75.5, 75.3, 74.8, 74.2, 74.1, 74.0, 73.1, 73.1, 73.0, 72.4, 68.6, 
45.9 (NEt3), 39.0, 27.3, 27.1, 19.4, 9.2(NEt3). 
HRMS-MALDI (m/z): [M-NEt3-H]-Calcd for C68H78O14PSi, 1177.4898; Found, 
1177.0978. 
31P NMR (162 MHz, CDCl3): δ 1.31. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-[2,3,4,6,-tetra-O-benzyl-β-D-
galactopyranosyl-]-α-D-mannopyranosyl phosphate triethylammonium salt 7. 
Triethylammonium (2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-
galactopyranosyl)-(1-4)- 2-O-trimetylacetyl-3,6-di-O-benzyl-β-D-mannopyranosyl 
hydrogen phosphonate 6 (0.1 g, 0.08 mmol) and 3-
(perfluorooctyl)propanyloxybutenyl alcohol25 (43 mg, 0.08 mmol) were coevaporated 
with pyridine and dried under high vacuume for 30 min. To a solution of this mixture 
in pyridine (3 mL) was added a solution of pivaloyl chloride (0.02 mL, 0.16 mmol) in 
pyridine (0.5 mL) and then the mixture was stirred at 25 oC for 1 h under nitrogen gas 
environment. To the reaction mixture was added a solution of iodine (20 mg, 0.008) in 
pyridine/water mixture (0.2 mL, 10/1) and the reaction mixture was quenched with 
saturated Na2S2O3. Excess pyridine was evaporated under reduced pressure and then 
the crude product was purified by flash silica column chromatography (with 
triethyamine) to afford the desired product 7 (0.12 g, 87 %). 
Rf (10 % MeOH in DCM): 0.6. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.33-6.89 (m, 35H), 5.72 (m, 1H), 5.54 
(m ,1H), 5.47 (d, 1H, J = 8.4 Hz), 5.45 (s, 1H), 5.04 (d, 1H, J = 11.2 Hz), 4.78-4.69 
111 
(m, 5H), 4.62 (d, 1H, J = 7.2 Hz), 4.57-4.54 (m, 3H), 4.49-4.41 (m, 3H), 4.37-4.34 (m, 
2H), 4.10 (t, 1H, J = 9.6 Hz), 4.02-3.88 (m, 4H), 3.78-3.68 (m, 3H), 3.45-3.33 (m, 
4H), 3.13 (dd, 1H, J = 9.2, 4.8 Hz), 2.13-2.09 (m, 2H), 1.80-1.76 (m, 2H), 0.98 (s, 9H), 
0.91 (s, 9H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 177.3 (C=O), [139.5, 139.2, 139.1, 138.9, 
138.9 (Cq-Aryl)], 135.6, 133.5, 133.4, [129.8-126.7 (m, CH-Aryl)], [103.3, 94.4 
(CHanomeric)], 82.6, 80.2, 74.2, 74.0, 73.0, 72.5, 70.7, 68.7, 68.7, 61.7, 61.2,  45.9 
(NEt3), 38.9, 28.4, 28.2, 28.0, 27.1, 19.4, 8.7 (NEt3). 
HRMS-MALDI (m/z): [M-NEt3-H]-Calcd for C83H89F17O16PSi, 1723.5386; Found, 
1722.8274. 
31P NMR (162 MHz, CDCl3)δ -1.44 
 
ASW Leishmania-phosphoglycan repeats method run 
  After FSPE, the methanol elution collected in the vial was removed from the 
instrument and concentrated. Solvent was removed under reduced pressure to obtain 
the crude product (30 mg) as colorless oil. In order to obtain pure product 8 (19 mg, 
10 %) for 1H NMR, 13 C NMR and mass spectrum, further purification was performed 
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using prep TLC.  
 
- 2.5 cycles (24h 56 min 39 sec) completed for the synthesis of phosphoglycan repeats. 
 
Step Task Reagent/ Operation Operation 
Time 
1 
 
 
 
2 
3 
4 
 
5 
6 
7 
8 
9 
10 
 
Coupling 
 
 
 
Oxidation 
Quenching  
Evaporation 
 
TLC sample 
FSPE 
Deprotection 
TLC sample 
Evaporation 
FSPE 
preparation 
Sample 
2 equivalent donor  (100 µmol) in 0.5 mL 
Pyridine,  
1 equivalent F-tagged acceptor (50 µmol) in 0.5 
mL Pyridine; 1 equivalent Piv-Cl  
I2 in Pyridine/Water (0.3 mL) 
Na2S2O3 (0.2 mL) 
Add TEA and Toluene 
70 oC 
30 µl of crude reaction mixture withdrawn 
 
5 equivalent of TBAF solution in THF 
30 µl of crude reaction mixture withdrawn 
70 oC 
0.4 ml DMF 
0.7 ml crude sample transferred to cartridge 
4.7 ml 80% methanol wash 
2 h 
 
 
 
 
1h 
  
2 h 
 
 
3 h 
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loading 
   Wash 
Wash 
Transfer 
Evaporation 
Transfer 
Evaporation 
1.5 ml methanol wash (repeated 3 times) 
4.7 ml collected sample transferred to clean vial 
 
50 oC 
2 ml toluene added 
50 oC 
 
45 min 
 
45 min 
 
Synthesis of Phosphoglycan repeats 8. 
Rf (10 % MeOH in DCM): 0.55. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.50-6.85 (m, 85H), 5.75 (m, 1H), 5.53-5.47 
(m, 3 H), 5.41 (s, 1H), 5.34 (s, 1H), 5.04 (d, 1H, J = 8 Hz), 4.90 (d, 1H, J = 12 Hz), 
4.79-4.66 (m, 11H), 4.63-4.48 (m, 12H), 4.45-4.35 (m, 8H), 4.28 (d, 2H, J = 12 Hz), 
4.19-4.06 (m, 10H), 3.98-3.80 (m, 11H), 3.76-3.67 (m, 5H), 3.63-3.53 (m, 5H), 3.41-
3.31 (m, 6H), 3.12-3.09 (m, 2H), 2.15-2.03 (m, 2H), 1.84-1.81 (m, 2H), 1.23 (s, 9H), 
1.10 (s, 9H), 0.98 (s, 9H), 0.87 (s, 9H).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) [178.2, 177.5, 177.1 (C=O)], 151.0, [139.7-
138.7 (Cq-Aryl)], 133.4, 133.3, [129.8-126.7 (m, CH-Aryl)], [103.2,103.2, 103.0, 94.5, 
94.3, 94.2 (CHanomeric)], 82.6, 82.6, 80.2, 80.2,75.9,75.1, 74.8, 73.9, 72.9, 72.7, 72.4, 
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72.2, 68.9, 68.7, 68.0, 66.7, 62.7, 61.6, 61.1, 59.2, 57.0, 45.9 (NEt3), 39.1, 38.9, 31.6, 
28.7, 27.3, 27.1, 24.3, 21.0, 19.4, 19.2, 13.9, 18.9, 8.7 (NEt3). 
HRMS-MALDI (m/z): [M-2NEt3-3H]3-Calcd for C189H210F17NO44P3Si, 3641.2936; 
Found, 3641.3557. 
31P NMR (162 MHz, CDCl3)δ -0.76, -1.24, -1.32. 
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Synthesis of (perfluorooctyl)propanyloxybutenyl- hydrogen phosphonate 9. 
(Perfluorooctyl)propanyloxybutenyl alcohol25 (0.1 g, 0.18 mmol) and phosphonic 
acid (30 mg, 0.36 mmol) were coevaporated with pyridine and dried under high 
vacuume for 30 min. To a solution of this mixture in pyridine (5 mL) was added a 
solution of pivaloyl chloride (0.045 mL, 0.36 mmol) in pyridine (2 mL) and then the 
mixture was stirred at 25 oC for 30 min under nitrogen gas environment. Prydine was 
removed under reduced vacuum and the crude product was purified by flash silica 
column chromatography (with triethylamine) to afford the desired product 9 (0.11 g, 
82 %). 
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Rf (10 % MeOH in DCM): 0.7 
1H NMR (CDCl3, 400 MHz): δ (ppm) 6.83 (d, 1H, JHP = 685 Hz), 5.77-5.71 (m, 1H), 
5.65-5.59 (m, 1H), 4.46 (t ,1H, J = 8 Hz), 4.04 (d, 1H, J = 6 Hz), 3.45 (d, 2H, J = 6 
Hz), 2.21-2.07 (m, 2H), 1.86-1.79 (m, 1H).  
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Synthesis of Vinyl-O-(3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-
Dmannopyranosyl)-α-D-mannopyranoside 10. 
To a solution of allyl-O-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-
Dmannopyranosyl)-α-D-mannopyranoside (0.15 g, 0.08 mmol) in THF (3 mL) was 
added catalytic amount of (1,5-
Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (7 mg, 
0.008 mmol). The stirred solution was degassed, placed under N2 and degassed. The 
reaction mixture was placed under H2 for 1 min and degassed once more to prevent 
further reduction.  The mixture was stirred at 25 oC for 1 h under N2 and then 
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concentrated under reduced vacuum. The crude residue was purified by flash silica 
column chromatography to afford the desired product 10 (0.14, 95 %). 
Rf (ethyl acetate/haxane): 0.63 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.33-7.15 (m, 30H), 6.07 (d, 1H, J = 12 Hz), 
5.54 (s, 1H), 5.12 (d, 1H, J = 20 Hz), 5.05-5.05 (m, 1H), 4.85-4.82 (m, 2H), 4.72-4.62 
(m, 5H), 4.55 (d, 2H, J = 12 Hz), 4.48-4.43 (m, 4H), 4.39 (d, 1H, J = 8 Hz), 4.05 (d, 
1H, J = 16 Hz), 3.96-3.89 (m, 3H) 3.84-3.66 (m, 6H), 2,12 (s, 3H), 1.49 (d, 3H, J = 8 
Hz). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.3 (C=O), 142.6, [138.7, 138.6, 138.5, 
138.4, 138.2 (Cq-Aryl)], [128.6-127.6 (m, CH-Aryl)], 104.8, [99.9, 98.3 (CHanomeric)], 
79.7, 78.4, 75.4, 75.3, 74.6, 73.6, 73.4, 72.4, 72.2, 69.3, 69.2, 69.0, 21.4, 12.6. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C59H64NaO12, 988.1220; Found, 988.3250. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-
acetyl-3,4,6-tri-O-benzyl-α-Dmannopyranosyl)-α-D-mannopyranosyl phosphate 
10-1.
To a vinyl-O-(3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-
Dmannopyranosyl)-α-D-mannopyranoside 9 (0.1 g, 0.1 mmol), and mercury oxide 
(31 mg, 0.14 mmol) in 4 mL of acetone/H2O (10/1)  was added a solution of 
mercuric chloride (31 mg, 0.11 mmol) in 4 mL of acetone/H2O (10/1) for 1 min. The 
reaction mixture was stirred at 25 oC for 3 h. The crude residue was filtered through 
celite and diluted with dichloromethane (5 mL). The organic layer was washed with 
sat. KI (1 x 5 mL), H2O (1 x 5 mL) and brine (1 x 5 mL). The solvent was dried with 
Na2SO4 and concentrated under reduced vacuum. The crude residue was purified by 
flash silica column chromatography to afford the hydrolyzed product (90 mg, 94 %). 
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The hydrolyzed product (50 mg, 0.05 mmol) and triethylammonium 3-
(perfluorooctyl)propanyloxybutenyl- hydrogen phosphonate (39 mg, 0.05 mmol) were 
coevaporated with pyridine and dried under high vacuume for 30 min. To a solution of 
this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.013 mL, 
0.1 mmol) in pyridine (0.5 mL) and then the mixture was stirred at 25 oC for 30 min 
under nitrogen gas environment. To the reaction mixture was added a solution of 
iodine (13 mg, 0.05) in pyridine/water mixture (0.2 mL, 10/1) and the reaction 
mixture was quenched with saturated Na2S2O3. Excess pyridine was evaporated under 
reduced pressure and then the crude product was purified by flash silica column 
chromatography (with triethyamine) to afford the desired product 10-1 (67 mg, 82 %). 
Rf (10 % MeOH in DCM): 0.65 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.28-7.06 (m, 30H), 5.66-5.61 (m, 1H), 5.57-
5.54 (m, 1H), 5.50 (s, 1H), 5.05 (s, 1H), 4.78 (t, 1H, J = 10.4 Hz), 4.68 (d, 1H, J = 12 
Hz), 4.63-4.61 (m, 3H), 4.54 (d, 1H, J = 16 Hz), 4.47-4.34 (m, 7H), 4.02 (br, 1H), 
3.94-3.89 (m, 6H), 3.86 (d, 1H, J = 12 Hz), 3.79-3.72 (m, 2H), 3.65 (d, 1H, J = 12 Hz), 
3.59 (br, 2H), 3.40 (br, 1H), 3.34 (t, 2H, J = 8 Hz), 2.14-2.02 (m, 2H), 2.08 (s, 3H), 
1.79-1.72 (m, 2H).    
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13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.2 (C=O), [138.4, 138.4, 138.2, 138.0, 
138.0 (Cq-Aryl)], [128.5-127.4 (m, CH-Aryl)], [99.7, 95.0 (CHanomeric)], 79.2, 78.1, 
75.2, 75.1, 74.1, 73.2, 72.8, 72.2, 72.0, 71.9, 68.9, 68.8, 68.7, 68.4, 66.5, 61.8, 28.1, 
27.9, 27.5, 21.0. 
31P NMR (162 MHz, CDCl3):δ -3.84 
HRMS-MALDI (m/z): [M-NEt3] Calcd for C71H72F17O16P, 1535.2684; Found, 
1535.4162. 
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Synthesis of Vinyl-O-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-
D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]- α-D- 
mannopyranoside 11. 
To a solution of allyl-O-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-
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D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-annopyranoside 
(0.11 g, 0.08 mmol) in THF (3 mL) was added catalytic amount of (1,5-
Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (3 mg, 
0.004 mmol). The stirred solution was degassed, placed under N2 and degassed. The 
reaction mixture was placed under H2 for 5 min and degassed once more to prevent 
further reduction.  The mixture was stirred at 25 oC for 30 min under N2 and then 
concentrated under reduced vacuum. The crude residue was purified by flash silica 
column chromatography to afford the desired product 11 (0.103 g, 94 %). 
Rf (ethyl acetate/haxane): 0.70 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.33-7.14 (m, 45H), 6.05 (d, 1H, J = 12 Hz), 
5.54 (s, 1H), 5.19 (d, 1H, J = 8 Hz), 5.06-5.05 (m, 1H), 5.03 (s, 1H), 4.85 (d, 1H, J = 
12 Hz), 4.70-4.50 (m, 14H), 4.45-4.41 (m, 3H), 4.32 (d, 1H, J = 12 v), 4.09 (br, 1H), 
4.01-3.89 (m, 9H), 3.83-3.81 (m, 2H), 3.73-3.64 (m, 6H), 3.54 (d, 1H, J = 12 Hz), 
2.13 (s, 3H), 1.47 (d, 3H, J = 4 Hz). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.3 (C=O), 142.2, [138.8, 138.7, 138.6, 
138.6, 138.6, 138.5, 138.4, 138.2 (Cq-Aryl)], [128.6-127.6 (m, CH-Aryl)], 104.6, 
[100.9, 99.6, 98.3 (CHanomeric)], 79.4, 78.3, 75.4, 75.3, 75.2, 74.9, 74.7, 74.5, 73.6, 
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73.5, 73.4, 72.5, 72.3, 72.1, 69.8, 69.3, 69.1, 69.0, 21.4, 12.6. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C86H92NaO17 1420.6302; Found, 
1420.4338. 
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3-(Perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl]- α-D-mannopyranosyl phosphate 11-1. 
To a vinyl-O-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside 11 
(0.1 g, 0.07 mmol), and mercury oxide (22 mg, 0.1 mmol) in 3 mL of acetone/H2O 
(10/1)  was added a solution of mercuric chloride (21 mg, 0.08 mmol) in 3 mL of  
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acetone/H2O (10/1) for 1 min. The reaction mixture was stirred at 25 oC for 4 h. The 
crude residue was filtered through celite and diluted with dichloromethane (5 mL). 
The organic layer was washed with sat. KI (1 x 5 mL), H2O (1 x 5 mL) and brine (1 x 
5 mL). The solvent was dried with Na2SO4 and concentrated under reduced vacuum. 
The crude residue was purified by flash silica column chromatography to afford the 
hydrolyzed product (92 mg, 95 %). 
The hydrolyzed product (50 mg, 0.04 mmol) and triethylammonium 3-
(perfluorooctyl)propanyloxybutenyl- hydrogen phosphonate (26 mg, 0.04 mmol) were 
coevaporated with pyridine and dried under high vacuume for 30 min. To a solution of 
this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.009 mL, 
0.08 mmol) in pyridine (0.3 mL) and then the mixture was stirred at 25 oC for 30 min 
under nitrogen gas environment. To a solution of this mixture in pyridine (3 mL) was 
added a solution of pivaloyl chloride (0.013 mL, 0.1 mmol) in pyridine (0.5 mL) and 
then the mixture was stirred at 25 oC for 30 min under nitrogen gas environment. To 
the reaction mixture was added a solution of iodine (9 mg, 0.04) in pyridine/water 
mixture (0.2 mL, 10/1) and the reaction mixture was quenched with saturated 
Na2S2O3. Excess pyridine was evaporated under reduced pressure and then the crude 
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product was purified by flash silica column chromatography (with triethyamine) to 
afford the desired product 11-1 (62 mg, 81 %). 
Rf (10 % MeOH in DCM): 0.68 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.26-7.09 (m, 45H), 5.64-5.58 (m, 1H), 5.54-
5.46 (m, 3H), 5.19 (s, 1H), 5.05 (s, 1H), 4.79 (d, 1H, J = 8 Hz), 4.76 (d, 1H, J = 8 Hz), 
4.67 (d, 1H, J = 12 Hz), 4.61 (d, 1H, J = 8 Hz), 4.56 (d, 1H, J = 4), 4.53-4.50 (m, 4H), 
4.47-4.44 (m, 4H), 4.39-4.32 (m, 4H), 4.25 (d, 1H, J = 12 Hz), 4.10 (d, 1H, J = 28 Hz), 
3.95-3.85 (m, 9H), 3.81 (d, 1H, J = 8 Hz), 3.74-3.69 (m, 2H), 3.65-3.56 (m, 4H), 3.44 
(d, 1H, J = 8 Hz), 3.39 (t, 1H, J = 4 Hz), 3.30 (t, 2H, J = 8 Hz), 2.12-1.99 (m, 2H), 
2.09 (s, 3H), 1.76-1.69 (2H).  
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.3 (C=O), [138.4, 138.2, 138.2, 138.1, 
138.1, 138.0, 137.9,  137.8 (Cq-Aryl)], [128.4-127.4 (m, CH-Aryl)], [100.2, 99.2. 
95.1 (CHanomeric)], 79.1, 78.2, 75.1, 75.1, 74.5, 74.4, 74.3, 74.2, 74.1, 73.4, 73.2, 72.7, 
72.5, 72.1, 72.1, 71.9, 71.8, 69.0, 68.7, 68.5, 61.7, 61.6, 49.2, 46.3 (NEt3),28.1, 27.8, 
27.6, 21.1, 8.6 (NEt3).  
31P NMR (162 MHz, CDCl3): δ -3.36 
HRMS-MALDI (m/z): [M-NEt3] Calcd for C98H100F17O21P 1967.7766; Found, 
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1967.4717. 
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Synthesis of Vinyl-O-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D- 
galactopyranosyl-]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-β-
D-mannopyranoside 12. 
To a solution of vinyl O-(2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-
hydroxy-3,6-di-O-benzyl-β-D-mannopyranoside24 (0.2 mg, 0.2 mmol) and 2-O-
acetyl-3,4,6-tri-O-benzylyl-α-D-mannopyranosyl tricholoroacetimidate (0.15 g, 0.22 
mmol) in dry toluene (5 mL) was added TMSOTf (3 µL, 0.02 mmol) at 25 oC. The 
reaction mixture was stirred at 25 oC for 10 min. The reaction was quenched with 
triethylamine (0.1 mL) and concentrated under reduced pressure. The crude product 
was purified by flash silica column chromatography to afford the desired product 12 
(0.27 g, 89 %). 
Rf (ethyl acetate/haxane):  0.63 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.31-7.14 (m, 45H), 6.22 (d, 1H, J = 8 Hz), 
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5.59 (s, 1H), 5.15 (s, 1H), 5.03-4.98 (m 1H), 4.91-4.79 (m, 4H), 4.72-4.62 (m, 8H), 
4.54-4.30 (m, 11H), 4.23 (d, 1H, J = 12 Hz), 4.12 (t, 1H, J = 8 Hz), 4.05 (dd, 1H, J = 
8, 4 Hz), 3.91-3.88 (m, 4H), 3.83 (dd, 1H, J = 8, 4 Hz), 3.75-3.69 (m, 3H), 3.66-3.45 
(m, 6H), 3.40-3.36 (m, 2H), 2.04 (s, 3H), 1.56 (dd, 3H, J = 16, 8 Hz).  
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.0 (C=O), 144.0, [139.3, 139.2, 139.0, 
139.0, 138.9, 138.7, 138.6 138.4 (Cq-Aryl)], [128.6-127.1 (m, CH-Aryl)], 104.1, 
[103.5, 99.9, 98.8 (CHanomeric)], 82.9, 80.2, 79.9, 78.9, 76.2, 75.5, 75.1, 74.8, 74.6, 
73.7, 73.6, 73.4, 73.1, 72.7, 72.3, 71.7, 69.4, 69.2, 68.9, 68.4, 21.4, 12.7. 
HRMS-MALDI (m/z): [M]+Calcd for C86H92O17, 1397.6405; Found, 1397.3901. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-
tetra-O-benzyl-β-D-galactopyranosyl-]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl- α -D-
mannopyranosyl]-α-D-mannopyranosyl phosphate 12-1. 
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To a vinyl-O-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl-]-
2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside 11 
(0.1 g, 0.07 mmol), and mercury oxide (22 mg, 0.01 mmol) in 5 mL of acetone/H2O 
(10/1)  was added a solution of mercuric chloride (21 mg, 0.08 mmol) in 5 mL of  
acetone/H2O (10/1) for 1 min. The reaction mixture was stirred at 25 oC for 3 h. The 
crude residue was filtered through celite and diluted with dichloromethane (5 mL). 
The organic layer was washed with sat. KI (1 x 5 mL), H2O (1 x 5 mL) and brine (1 x 
5 mL). The solvent was dried with Na2SO4 and concentrated under reduced vacuum. 
The crude residue was purified by flash silica column chromatography to afford the 
hydrolyzed product (85 mg, 88 %). 
The hydrolyzed product (50 mg, 0.04 mmol) and triethylammonium 3-
(perfluorooctyl)propanyloxybutenyl- hydrogen phosphonate (26 mg, 0.04 mmol) were 
coevaporated with pyridine and dried under high vacuume for 30 min. To a solution of 
this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.009 mL, 
0.08 mmol) in pyridine (0.3 mL) and then the mixture was stirred at 25 oC for 30 min 
under nitrogen gas environment. To a solution of this mixture in pyridine (3 mL) was 
added a solution of pivaloyl chloride (0.013 mL, 0.1 mmol) in pyridine (0.5 mL) and 
127 
then the mixture was stirred at 25 oC for 30 min under nitrogen gas environment. To 
the reaction mixture was added a solution of iodine (9 mg, 0.04) in pyridine/water 
mixture (0.2 mL, 10/1) and the reaction mixture was quenched with saturated 
Na2S2O3. Excess pyridine was evaporated under reduced pressure and then the crude 
product was purified by flash silica column chromatography (with triethyamine) to 
afford the desired product 12-1(63 mg, 83 %). 
Rf (10 % MeOH in DCM): 0.68 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.26-7.14 (m, 45H), 5.66-5.64 (m, 1H), 5.56-
5.45 (m, 3H), 5.09 (d, 1Hanomeric, J = < 1 Hz), 4.97 (d, 1H, J = 12), 4.76 (d, 1H, J = 12 
Hz), 4.76 (d, 1H, J = 12 Hz), 4.67-4.56 (m, 5H), 4.52-4.35 (m, 8H), 4.31-4.24 (m, 4H), 
4.17 (d, 1H, J = 8 Hz), 4.12 (t, 1H, J = 8 Hz), 4.03 (br, 1H), 3.94 (m, 8H), 3.74-3.60 
(m, 5H), 3.51 (t, 1H, J = 8 Hz), 3.40-3.37 (m, 3H), 3.33 (t, 2H, J = 8 Hz), 2.15-2.06 
(m, 2H), 2.01 (s, 3H), 1.79-1.72 (m, 2H).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 169.8 (C=O), [139.1, 139.0, 138.8, 138.4, 
138.3, 138.1, 138.1, 138.0, 137.9 (Cq-Aryl)], [128.3-127.0 (m, CH-Aryl)], [103.2, 
99.6. 95.0 (CHanomeric)], 82.0, 79.9, 78.4, 75.9, 75.2, 74.6, 74.0, 73.3, 73.2, 73.0, 72.7, 
72.4, 71.9, 71.8,68.7, 66.5, 61.8, 61.7,46.2, 28.1, 27.7, 27.1, 21.0. 
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31P NMR (162 MHz, CDCl3): δ -2.99 
HRMS-MALDI (m/z): [M-NEt3] Calcd for C98H100F17O21P 1967.7766; Found, 
1967.3716. 
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Synthesis of Vinyl-O-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D- 
galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-
mannopyranoside 13. 
To a solution of allyl-O-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D-
galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside (0.2 g, 0.11 mmol) in 
THF (5 mL) was added catalytic amount of (1,5-
Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (10 mg, 
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0.011 mmol). The stirred solution was degassed, placed under N2 and degassed. The 
reaction mixture was placed under H2 for 5 min and degassed once more to prevent 
further reduction.  The mixture was stirred at 25 oC for 30 min under N2 and then 
concentrated under reduced vacuum. The crude residue was purified by flash silica 
column chromatography to afford the desired product 13 (0.19 g, 93 %). 
Rf (ethyl acetate/haxane):  0.70 (25/75)  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.30-7.16 (m, 60H), 6.18 (d, 1H, J =12 Hz), 
5.50 (s, 1H), 5.17 (s, 1H), 5.02-4.98 (m 1H), 4.93 (t, 2H, J = 6.4 Hz), 4.81 (t, 2H, J = 
10.4 Hz), 4.74 (br, 2H), 4.66-4.65 (m, 4H), 4.63 (d, 1H, J = 10.4 Hz), 4.58 (d, 1H, J = 
11.2 Hz), 4.51-4.40 (m, 7H), 4.35 (d, 1H, J = 10.8 Hz), 4.27-4.25 (m, 2H), 4.21-4.18 
(m, 2H), 4.06 (t, 1H, J = 8 Hz), 4.01-3.90 (m, 7H), 3.86 (d, 2H, J = 9.2 Hz), 3.80-3.71 
(m, 3H), 3.66 (d, 1H, J = 10.4 Hz), 3.61-3.48 (m, 6H), 3.45 (dd, 1H, J = 7.2, 2 v), 3.38 
(d, 2H, J = 4.4 Hz), 2.07 (s, 3H), 1.51 (d, 3H, J = 6.8 Hz).    
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.2 (C=O), 144.0, [139.1, 139.1, 138.9, 
138.9, 138.8, 138.8, 138.6, 138.3, 138.2 (Cq-Aryl)], [128.5-127.3 (m, CH-Aryl)], 
103.9, [103.0, 100.4, 99.6, 98.7 (CHanomeric)], 80.0, 79.7, 79.2, 78.4, 75.8, 75.4, 75.1, 
74.9, 74.6, 74.6, 73.5, 73.4, 73.3, 73.0, 72.9, 72.8, 72.2, 72.1, 72.1, 69.5, 69.4, 69.3, 
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69.1, 68.5, 21.4, 12.6. 
HRMS-MALDI (m/z): [M]+Calcd for C113H120O22, 1828.8271; Found, 1828.4955. 
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Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-
tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-
D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-
mannopyranosyl phosphate 13-1. 
To a vinyl-O-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl]-
2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-
D-mannopyranosyl]-α-D-mannopyranoside 12 (0.1 g, 0.06 mmol), and mercury oxide 
(17 mg, 0.14 mmol) in 4 mL of acetone/H2O (10/1) was added a solution of mercuric 
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chloride (16 mg, 0.06 mmol) in 3 mL of acetone/H2O (10/1) for 1 min. The reaction 
mixture was stirred at 25 oC for 3 h. The crude residue was filtered through celite and 
diluted with dichloromethane (5 mL). The organic layer was washed with sat. KI (1 x 
5 mL), H2O (1 x 5 mL) and brine (1 x 5 mL). The solvent was dried with Na2SO4 and 
concentrated under reduced vacuum
. 
The crude residue was purified by flash silica 
column chromatography to afford the hydrolyzed product (82 mg, 84 %). 
The hydrolyzed product (50 mg, 0.03 mmol) and triethylammonium 3-
(perfluorooctyl)propanyloxybutenyl- hydrogen phosphonate (20 mg, 0.03 mmol) were 
coevaporated with pyridine and dried under high vacuume for 30 min. To a solution of 
this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.007 mL, 
0.06 mmol) in pyridine (0.3 mL) and then the mixture was stirred at 25 oC for 30 min 
under nitrogen gas environment. Prydine was removed under reduced vacuum and the 
crude product was purified by flash silica column chromatography (with triethyamine) 
to afford the desired product 13-1 (59 mg, 84 %). 
Rf (10 % MeOH in DCM): 0.69 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.26-7.05 (m, 60H), 5.64-5.59 (m, 1H), 5.53-
5.45 (m, 3H), 5.13 (d, 1Hanomeric, J = < 1 Hz), 4.91 (d, 1H, J = 12 Hz), 4.79 (d, 1H, J = 
132 
8 Hz), 4.74 (d, 1H, J = 8 Hz), 4.67-4.57 (m, 5H), 4.54-4.36 (m, 11H), 4.29 (t, 2H, J = 
12 Hz), 4.23 (d, 1H, J = 8 Hz), 4.20 (d, 1H, J = 8 Hz), 4.14 (d, 1H, J = 12 Hz), 4.09-
4.05(m, 2H), 4.00-3.94 (m, 2H), 3.90-3.78 (m, 11H), 3.73-3.52 (m, 6H), 3.41 (d, 2H, J 
= 12 Hz), 3.34-3.27 (m, 4H), 2.12 (m, 2H), 2.03 (s, 3H), 1.76-1.69 (m, 2H).   
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.1 (C=O), [139.1, 139.0, 138.7, 138.5, 
138.4, 138.2, 138.1, 138.0, 138.0, 138.0 (Cq-Aryl)], [128.3-127.0 (m, CH-Aryl)], 
[103.2, 100.8, 99.3. 95.0 (CHanomeric)], 82.6, 79.9, 79.6, 75.2, 75.1, 74.7, 74.3, 74.1, 
73.2, 73.1, 73.0, 72.6, 72.5, 72.0, 71.9, 71.8, 68.7, 68.7, 68.5, 68.1, 66.4, 61.7, 61.7, 
49.5, 46.2 (NEt3), 28.1, 27.9, 27.7, 21.1, 8.6 (NEt3). 
31P NMR (162 MHz, CDCl3): δ -2.39 
HRMS-MALDI (m/z): [M-NEt3] Calcd for C125H128F17O26P 2400.2848; Found, 
2400.7329. 
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CHAPTER 5 
Synthesis of multivalent tuberculosis and Leishmania-associated capping 
carbohydrates and evaluation of structure-dependent immune responses in 
IL-12 production 
A paper to be submitted to Journal of the American Chemical Society   
Eun-Ho Song, Alex O. Osanya, Christine A. Petersen, and Nicola L. Pohl 
 
Microbacterium tuberculosis is an intracellular pathogen which survives in 
macrophages and remains as one of the severe infectious diseases due to large number 
of infections with more than 2 million deaths annually worldwide.1 Leishmaniasis is 
also an infectious disease caused by protozoan parasites of the genus Leishmania. 
Leishmaniasis is endemic over much of 88 countries in Africa, India, southern Europe, 
and Central and South America.2 Importantly, M. tuberculosis3 and leishmaniasis4 are 
particularly problematic in these areas as a reactivating infection in AIDS patients. 
Despite considerable progress devoted to preventing and controlling tuberculosis and 
leishmaniasis, the disease still remains beyond efficient medical treatments such as 
vaccines. Therapies, including vaccines, have to deal with the parasites’ ability to hide 
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in human macrophage cells—the white bloods cells that usually engulf and eliminate 
foreign materials. Herein we present the synthesis and development of new chemical 
tools which demonstrates that only simple changes in parasite-associated surface 
oligosaccharides are sufficient to change cellular immune responses and thereby let a 
parasite hide from immune surveillance. 
The most abundant molecules found on the cell surfaces of bacteria, parasites and 
viruses are carbohydrates.5 Due to structural distinctions among host cells and the 
distribution of carbohydrates on the outer surface of the cell, structure-function 
relationships involving carbohydrates have drawn attention amongst both synthetic 
organic chemists and immunologists. However, obtaining well-defined carbohydrate 
structures has been challenging due to limitations associated with current isolation 
protocols.6 Simple commercially available sugars can be readily attached to beads for 
the identification of monosaccharide-dependent immunity7; however, these protocols 
do not lend themselves readily to larger structurally well-defined oligosaccharides.  
 
137 
1. O3, PPh3
2. Jones reagent
    85 % (2 steps)
Na, NH3
THF, 90 %
1 2 3 4
O
BnO
BnO
OAc
O
BnO
NH
CCl3 OBnO
BnO
O
O
BnO
O
BnO
BnO
OBnO
O
BnO
BnO
OAcBnO
OC8F17
O
BnO
BnO
O
O
BnO
O
BnO
BnO
OBnO
O
BnO
BnO
OAcBnO
OH
O
O
HO
HO
O
O
HO
O
HO
HO
OHO
O
HO
HO
OHHO
OH
O
GPI Anchor Mannose Phosphate Core Arabinan branched polymers Cap
GPI Anchor CapPhosphoglycan repeats
- M. tuberculosis
- Leishmania
 
Figure 1. Capping structure in lipoarabinomannan (LAM) of M. tuberculosis and 
lipophosphoglycan (LPG) of Leishmania. 
 
As shown in Figure 1, trimannose is one of the major components both in LPG of 
Leishmania parasites8 and LAM of M. tuberculosis cell wall.9 To date, several 
synthetic approaches have been reported to construct Leishmania capping structures 
including oligomannose10 and branched oligosaccharide11 for the purpose of synthetic 
challenge or vaccine development12. We wanted to develop a viable route to a range of 
Leishmania capping structures including trimannose and lactose as a control.   
With this purpose, we envisioned making essentially artificial parasites of the same 
size (one micron) as Leishmania that contain only the structurally well-defined 
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capping polysaccharide associated with pathogens. The key challenge in the synthesis 
of artificial pathogens is construction of multivalent effect on latex beads in order to 
give more chance to induce immune responses.   
 
Results and discussion 
Trimannose can be prepared fluorous solid-phase extraction (FSPE)-based iterative 
synthesis as reported in literature10 (Scheme 1). Mannose trichloroacetimidate 1 was 
prepared from tri-O-benzyl orthoester intermediate13. Acid (TMSOTf)-activated 
glycosylation of mannose trichloroacetimidate with fluorous-tag gave fluorous-tagged 
disaccharide for further iterative synthesis of capping structures. This iterative 
synthesis using fluorous-solid-phase extraction (FSPE) takes advantage of the fact 
that desired oligosaccharide can be prepared without conventional slica-column 
purification.14 The fluorous-tag in trimannose 2 was then cleaved with ozonolysis and 
subsequent oxidation with Jones reagent facilitates further coupling reaction of 
carboxylated-sugar with amine-functionalized beads. Global deprotection under 
Na/NH3 at -78 oC furnished fully deprotected trimannose 4 in good yield.  
Carboxylated-lactose was also efficiently prepared through conventional silica-
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column purification. (see Supporting information)  
With the capping sugar and the control sugar lactose in hand, a suitable one micron-
sized support was required for multivalent display of these sugars. Latex beads are 
commonly used in immunoassays due to their inertness and commercial availability. 
Moreover, beads with high concentrations of imbedded fluorophores enable various 
fluorescent assays.15  For example, such beads have been utilized for agglutination 
tests for the detection of antibodies16 or investigation of heparin-binding properties17, 
for the analysis of blood cell populations18, for the identification of specific cell 
membrane markers19 and for the measurement of sugar particle-induced immunity7. 
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Scheme 1. Synthesis of multivalent tuberculosis and Leishmania capping structures 
on latex beads. 
 
In this regard, we used commercially available Latex beads B0 (microspheres, 1µm 
diameter and yellow-green fluorescent) derivatized with carboxylate groups (3.5 x 10-
4 mmol carboxylate groups per mL). The chosen size of FITC-labeled latex beads 
mimics the size of the Leishmania parasite and allows use of a common 
immunofluorescent assay for the observation of the possible uptake of beads by 
macrophages. In order to avoid spatial proximity of sugars on the surface of the beads 
and improve the accessibility of sugars to possible macrophage binding partners, 
ethylenediamine as a spacer was attached to the carboxylated bead surface under 
standard peptide coupling conditions. Unfortunately, solvents for the coupling 
reaction were severely limited due to difficulties associated with the stability of the 
apparently noncovalent FITC linkage in organic solvents. Therefore, the choice of 
suitable solvent was an important consideration for both obtaining quantitative yield 
in coupling reaction and designing synthetic routes for sugars. Combined condition 
for coupling using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
141 
(EDC) and N-hydroxysuccinimide (NHS)20 in deionized water was utilized to make 
peptide linkages (Scheme 2).  
The subsequent coupling reaction of various capping structures containing the 
carboxylic acid linker with amine spacer on the beads gave Leishmania-associated 
capping carbohydrate coated-beads (Figure 1). Each coupling step was repeated twice 
with 30 ~ 50 equivalent of sugars to obtain a complete reaction. The density of sugar 
was calculated by given density of carboxylates (1.296 x 10-14 mmol / bead). As for 
coupling steps, Kaiser colorimetric test was used as an indicator of coupling reaction 
progress.21  
To evaluate structure-dependent immune responses, lactose coated beads B1 and 
trimannose-coated beads B2 were initially incubated with murine macrophages for the 
analysis of cytokine production including Interleukin-12 (IL-12).22 IL-12 plays a 
significant role in the link between innate and adaptive immunity 
 
 
 Figure 2. Effect of cap sugar coated
coated beads, and B2 = trimannose
by murine macrophage 
[Asterisks denote a significant change between the TLR2 blocking from cont
isotype and/or non-blocking
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As shown in Figure 2, comparable levels of IL12-p40 under two different 
environments including no blocking agents and isotype IgG1 antibody were produced 
when murine macrophages were stimulated by lactose-coated beads, whereas IL12 
production stimulated by trimannose-coated beads was significantly diminished. 
These results indicate that structure differences in carbohydrates exhibit clear 
differences in the activation of innate immune responses induced by only differences 
in the carbohydrate structure.  
In order to obtain more information about structure-dependent immune responses, 
other capping structures were also efficiently prepared through conventional silica-
column purification for galactose23 or FSPE-based purification for dimannose7, 
branched tri-and tetrasaccharide.24  
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Scheme 2. Iterative synthesis of fluorous-tagged Leishmania tetrasaccaride 
 
Branched Leishmania capping structures including trisaccharide 3 and 
tetrasaccharide 4 was also prepared either through iterative synthesis or automation 
platform.22 The fluorous-tag in tetrasaccharide was then cleaved with ozonolysis and 
subsequent oxidation with Jones reagent facilitates further coupling reaction of 
carboxylated-sugar with amine-functionalized beads. Global deprotection under 
Na/NH3 at -78 oC furnished fully deprotected saccharides (3-2 and 4-2) in good yield 
(Scheme 3).  
Other capping structures were also efficiently prepared through conventional silica-
column purification for galactose 5 or FSPE-based purification for dimannose 6.  
Carboxylated-Leishmania capping structures were then displayed on the latex beads 
under optimized coupling conditions (Figure 3). 
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Figure 3. Multivalent Leishmania capping structures on latex beads 
 
Conclusion 
In conclusion, we demonstrated that the protocol of preparation of artifical 
parasites including well defined tuberculosis and Leishmania-associated capping 
structures such as trimannose and lactose enabled the study of structure-dependent 
immune reponses. In particluar, fluorous phase-based iterative synthesis provides 
not only a convenient purification step but also an easy transformation to 
carboxylic acid in order to display capping structures on the latex beads surface. 
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More importantly, our results with preminary IL-12 production studies showed that 
structure differences in carbohydrates produced a distinct differences in IL-12 p40 
producton.  
These results could provide a standard strategy for unveiling innate immune 
mechanisms induced by specific carbohydrate structure 
 
Experimental section 
General methods 
Solvents were reagent grade and in most cases dried prior to use. All other 
commercially available reagents were used as received unless otherwise noted. The 
organic extracts were dried over anhydrous MgSO4. Tetrahydrofuran (THF) was 
distilled from lithium aluminum hydride (LiAlH4) prior to use. Methylene chloride 
(CH2Cl2), and triethylamine (Et3N) were distilled from calcium hydride. Diethyl ether 
(Et2O) was distilled from sodium-benzophenone ketyl.  
  
1H and 13C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-
400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an 
Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems 
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QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per 
million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are 
reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.   
 
Synthesis of Fully deprotected carboxylated-Leishmana capping structures. 
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Synthesis of Carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl]-
2,3,6-tri-O-acetyl-β-D-galactopyranoside 1. 
To a solution of 2-propynyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl] - 
2,3,6- tri-O-acetyl-β-D-galacto-pyranoside25  (0.5g, 0.7 mmol) in the mixture of CCl4 
(3 mL), CH3CN (3 mL), and H2O (4 mL) is added NaIO4 (1.27 g, 5.6 mmol). To this 
mixture was added RuCl3.H2O (3.1 mg, 2.2 mol %) and the reaction mixture was 
stirred at 25 oC for 2 h. After dilution with 10 mL of DCM, the reaction mixture was 
filtered through a Celite pad. The aqueous layer was extracted with twice with DCM 
and then organic layer was washed with water and brine. The crude mixture was 
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obtained after drying with Na2SO4 followed by concentration under reduced vacuum. 
The crude product was purified to obtain the desired product 1(0.47 g, 91 %) by silica 
column chromatography 
Rf (ethyl acetate/haxane): 0.30 (70/30) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 5.34 (d, 1H, J = 2.4 Hz), 5.22 (t, 1H, J = 9.2 
Hz), 5.09 (t, 1H, J = 8 Hz), 4.97-4.93 (m, 2H), 4.62 (d, 1H, J = 7.6 Hz), 4.50-4.47 (m, 
2H), 4.29 (s, 2H), 4.11-4.04 (m, 3H), 3.87 (t, 1H, J = 6.4 Hz), 3.80 (t, 1H, J = 9.2 Hz), 
3.65-3.61 (m, 1H), 2,14 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 
2.03 (s, 3H), 1.93 (s, 3H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.6, 170.6, 170.3, 170.3, 170.1, 169.9, 
169.2, [101.2, 100.4 (CHanomeric)], 76.2, 73.1, 72.5, 71.4, 71.1, 70.9, 69.2, 66.8, 65.5, 
61.9, 61.0, 21.0, 21.0, 20.9, 20.9, 2.08, 20.7.  
HRMS-MALDI (m/z): [M+Na]+Calcd for C28H38NaO20, 717.5791; Found, 717.6184. 
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2. 
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To a carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl]-2,3,6-tri-O-
acetyl-β-D-galacto-pyranoside (1) (0.4 g, 0.57 mmol) in MeOH (5 mL) was added Na 
(27 mg, 1.14 mmol) and stirred at 25 oC for 2 h. The reaction mixture was neutralized 
with Dowex-ion-exchange resin. The desired (2) was obtained through Celite 
filteration followed by evaporation of solvent under reduced pressure in good yield 
(0.21 g, 89 %).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 4.46 (d, 1H, J = 16.4 Hz), 4.30-4.23 (m, 2H), 
3.81 (d, 1H, J = 3.2 Hz). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 173.0, 170.8, 170.5, 17.4, 170.2, 100.4 
(CHanomeric), 71.1, 70.7, 68.6, 67.1, 65.0, 61.4, 21.0, 20.9, 20.8, 20.8. 
HRMS-ESI (m/z): [M+Na]+Calcd for C14H24NaO13, 423.1115; Found, 423.0942. 
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Synthesis of Carboxymethyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 3. 
To a solution of 2-propynyl-2,3,6-tri-O-acetyl-β-D-galacto-pyranoside20 (0.5 g, 1.29 
mmol) in the mixture of CCl4 (3 mL) , CH3CN (3 mL), and H2O (4 mL) is added 
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NaIO4 (2.2 g, 10.3 mmol). To this mixture was added RuCl3.H2O (6 mg, 2.2 mol %) 
and the reaction mixture was stirred at 25 oC for 2 h. After dilution with 10 mL of 
DCM, the reaction mixture was filtered through a Celite pad. The aqueous layer was 
extracted with twice with DCM and then organic layer was washed with water and 
brine. The crude mixture was obtained after drying with Na2SO4 followed by 
concentration under reduced vacuum. The crude product was purified to obtain the 
desired product (3) (0.42 g, 81 %) by silica column chromatography  
Rf (ethyl acetate/haxane): 0.25 (70/30) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 5.41 (d, 1H, J = 2.8 Hz), 5.25 (dd, 1H, J = 7.9, 
2.5 Hz), 5.06 (dd, 1H, J = 10.4, 3.3 Hz), 4.62 (d, 1H, J = 7.9), 4.36 (s, 2H), 4.20-4.09 
(m, 2H), 3.94 (t, 1H, J = 6.7 Hz), 2.16 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 173.0, 170.8, 170.5, 170.4, 170.2, 100.4 
(CHanomeric), 71.1, 70.7, 68.6, 67.1, 65.0, 61.4, 21.0, 20.9, 20.8, 20.8. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C16H22NaO12,429.1009; Found,  
 
O
OH
HO
HO
HO
O OH
OO
OAc
AcO
AcO
AcO
O OH
O
 
 
151 
Synthesis of Carboxymethyl-β-D-galactopyranoside 4. 
To a carboxymethyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (3) (0.4 g, 0.99 
mmol) in MeOH (5 mL) was added Na (45 mg, 1.98 mmol) and stirred at 25 oC for 2 
h. The reaction mixture was neutralized with Dowex-ion-exchange resin. The desired 
product (4) was obtained through Celite filteration followed by evaporation of solvent 
under reduced pressure in good yield (0.21 g, 89 %).  
1H NMR (CD3OD, 400 MHz): δ (ppm) 4.46 (d, 1H, J = 16.4 Hz), 4.30-4.23 (m, 2H), 
3.81 (d, 1H, J = 3.2 Hz), 3.75-3.68 (m, 2H), 3.60-3.53 (m, 1H), 3.51-3.47 (m, 2H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) 173.1, 103.4 (CHanomeric), 75.7, 73.4, 71.1, 
69.0, 65.5, 61.3. 
HRMS-ESI (m/z): [M+Na]+Calcd for C8H14NaO8, 261.0586; Found, 261.0463. 
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Synthesis of Carboxymethyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside 5. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-
acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (0.2 g, 0.15 
mmol) in DCM was bubbled O3 at -78 oC for 5 min. The light-blue solution was 
treated with PPh3 (58 mg, 0.23 mmol) and was allowed to warm to room temperature. 
After 30 min, the crude aldehyde product was obtained after concentration under 
reduced vacuum. To a solution of aldehyde product in acetone was added Jones 
reagent (0.16 mL, 0.13 mmol) and the mixture was stirred for 30 min. After TLC 
analysis, excess reagent was quenched with 2-propanol and sold was filtered off 
through a Celite pad. The pure product 5 (0.12 g, 89 %) was obtained after 
concentration under reduced vacuum followed by purified through silica column 
chromatography (Hexane:Ethyl Acetate = 1:2). 
Rf (ethyl acetate/haxane): 0.30 (70/30) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.33-7.15 (m, 30H), 5.52 (s, 1H), 5.07 (s, 1H), 
4.98 (s, 1H), 4.83 (dd, 2H, J = 10.8, 6 Hz), 4.68 (s, 2H), 4.67-4.60 (m, 3H), 4.53-4.39 
(m, 5H), 4.10-4.02 (m, 3H), 3.96-3.90 (m, 3H), 3.80-3.65 (m, 7H), 2.11 (s, 3H). 
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13
 C NMR (CDCl3, 100 MHz): δ (ppm) 173.5 (C=O), 170.5 (C=O), [138.7, 138.6, 
138.4, 138.3 (Cq-Aryl)], 128.7-127.8 (m, CH-Aryl), [99.8, 99.0 (CHanomeric)], 79.7, 
78.4, 75.4, 74.7, 73.7, 73.6, 72.7, 72.4, 72.3, 72.2, 69.4, 69.2, 69.1, 63.7, 21.4 (CH3). 
HRMS-MALDI (m/z): [M+Na]+Calcd for C58H62NaO14, 1005.4037; Found, 
1005.4289 
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Synthesis of Carboxymethyl-2-O-(2-O-α-D-mannopyranosyl)-α-D- 
mannopyranoside 6 
To a carboxymethyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-α-D-mannopyranoside (5) (0.1 g, 0.11 mmol) was dissolved in THF 
(8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed 
into the flask at -78 oC. Sodium metal was added in several portions until the solution 
was dark blue. The dark blue solution was stirred at -78 oC for 30 min. Following 
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disappearance of the dark blue color, EtOH (3 mL) was added and ammonia was 
blown off with a stream of air. The solution was then neutralized with acidic Dowex-
resin to pH 7 and the resin was filtered off through a Celite pad. The desired (6) was 
obtained through evaporation of solvent under reduced pressure in good yield (34 mg, 
75 %).   
1H NMR (CD3OD, 400 MHz): δ (ppm) 5.15 (s, 1H), 4.98 (s, 1H), 4.24 (m, 2H), 
3.96-3.57 (m, 12H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) 172.3 (C=O), [102.9, 98.7 (CHanomeric)], 
78.8, 78.8, 74.0, 73.7, 71.2, 70.6, 67.4, 63.7, 63.4, 61.8, 61.7. 
HRMS-ESI (m/z): [M+Na]+Calcd for C14H24NaO13, 423.1115; Found, 423.0923. 
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Synthesis of Carboxymethyl-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-
mannopyranoside 7. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-
acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (0.2 g, 0.11 
mmol) in DCM was bubbled O3 at -78 oC for 5 min. The light-blue solution was 
treated with PPh3 (42 mg, 0.16 mmol) and was allowed to warm to room temperature. 
After 30 min, the crude aldehyde product was obtained after concentration under 
reduced vacuum. To a solution of aldehyde product in acetone was added Jones 
reagent (0.11 mL, 0.08 mmol) and the mixture was stirred for 30 min. After TLC 
analysis, excess reagent was quenched with 2-propanol and sold was filtered off 
through a Celite pad. The pure product (7) (0.13 g, 87 %) was obtained after 
concentration under reduced vacuum followed by purified through silica column 
chromatography (Hexane:Ethyl Acetate = 1:2). 
Rf (ethyl acetate/haxane):  0.13 (50/50) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.26-7.12 (m, 45H, aromatics), 5.52 (t, 1H, J = 
2.0 Hz), 5.17 (s, 1H), 5.03 (d, 1H, J = 8.0 Hz), 4.83 (d, 1H, J = 10.8 Hz), 4.80 (d, 1H, 
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J = 10.8 Hz), 4.62-4.41 (m, 14H), 4.33 (d, 1H, J = 12.0 Hz), 4.10-4.05 (m, 3H), 4.05-
3.88 (m, 6H), 3.77-3.63 (m, 8H), 3.53 (d, 1H, J = 10.4 Hz), 2.12 (s, 3H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 172.4, 170.2, [138.6, 138.5, 138.5, 138.4, 
138.3, 138.3, 138.1 (Cq-Aryl)], 134.1 (CH2CH=CH2), 128.5 – 127.6 (m, CH-Aryl), 
[100.9, 99.5, 99.3 (CHanomeric)], 79.1, 78.1, 75.2, 75.2, 75.0, 74.9, 74.6, 74.3, 73.4, 
72.6, 72.5, 72.3, 72.2, 72.0, 71.9, 69.8, 69.2, 68.9, 68.8,  
HRMS-ESI (m/z): [M+Na]+Calcd for C85H90NaO19, 1437.5974; Found, 1437.5097. 
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Synthesis of Carboxymethyl-2-O-[2-O-(2-O-α-D-mannopyranosyl)-α-D- 
mannopyranosyl]-α-D-mannopyranoside 8. 
To a carboxymethyl-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside 7 
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(0.1 g, 0.07 mmol) was dissolved in THF (8 mL) and MeOH (0.5 mL) in a flask. 
Liquid ammonia (20 mL) was then condensed into the flask at -78 oC. Sodium metal 
was added in several portions until the solution was dark blue. The dark blue solution 
was stirred at -78 oC for 30 min. Following disappearance of the dark blue color, 
EtOH (3 mL) was added and ammonia was blown off with a stream of air. The 
solution was then neutralized with acidic Dowex-resin to pH 7 and the resin was 
filtered off through a Celite pad. The desired (8) was obtained through evaporation of 
solvent under reduced pressure in good yield (29 mg, 72 %).   
1H NMR (CD3OD, 400 MHz): δ (ppm) 5.29 (s, 1H), 5.11 (s, 1H), 4.97 (s, 1H), 4.02-
3.53 (m, 20H).  
13
 C NMR (CD3OD, 100 MHz): δ (ppm) 176.3 (C=O), [102.7, 101.1, 98.4 
(CHanomeric)], 79.1, 78.9, 73.7, 73.7, 73.5, 71.2, 70.8, 70.7,70.7, 67.9, 67.8, 67.5, 66.0, 
61.8, 61.7, 61.6. 
HRMS-ESI (m/z): [M+Na]+Calcd for C20H34NaO18, 585.1643; Found, 585.1528. 
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Synthesis of Carbpxymethyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D-
galactopyranosyl-]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-
D-mannopyranoside 9.
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-
[2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl-]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-
α-D-mannopyranosyl]-α-D-mannopyranoside (0.2 g, 0.11 mmol) in DCM was 
bubbled O3 at -78 oC for 5 min. The light-blue solution was treated with PPh3 (42 mg, 
0.16 mmol) and was allowed to warm to room temperature. After 30 min, the crude 
aldehyde product was obtained after concentration under reduced vacuum. To a 
solution of aldehyde product in acetone was added Jones reagent (0.11 mL, 0.08 
mmol) and the mixture was stirred for 30 min. After TLC analysis, excess reagent was 
quenched with 2-propanol and sold was filtered off through a Celite pad. The pure 
product 9 (0.13 g, 85 %) was obtained after concentration under reduced vacuum 
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followed by purified through silica column chromatography (Hexane:Ethyl Acetate = 
1:2). 
Rf (ethyl acetate/haxane): 0.12 (50/50) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.29-7.13 (m, 45H, aromatics), 5.45 (s, 1H), 
5.08 (s, 1H), 4.94 (d, 1H, J = 4 Hz), 4.90 (d, 1H, J = 12 Hz), 4.84-4.76 (m, 3H), 4.71-
4.44 (m, 9H), 4.41-4.25 (m, 7H), 4.19-4.15 (m, 3H), 3.95-3.87 (m, 3H), 3.80-3.64 (m, 
7H), 3.50 (t, 1H, J = 12 Hz), 3.43-3.38 (m, 2H), 2.07 (s, 3H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 173.3, 170.0, [139.2, 139.1, 139.0, 138.8, 
138.6, 138.5, 138.3, 138.2, 138.1 (Cq-Aryl)], 128.5–127.2 (m, CH-Aryl), [103.7, 99.3, 
99.1 (CHanomeric)], 82.8, 80.0, 78.5, 75.4, 75.3, 75.1, 74.8, 74.5, 73.5, 73.3, 73.1, 72.9, 
72.8, 72.5, 72.2, 72.1, 69.1, 69.0, 68.6, 68.4, 84.1, 21.3.  
HRMS-MALDI (m/z): [M+Na]+Calcd for C85H90NaO19, 1437.5974; Found, 
1437.7109.. 
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Synthesis of Carboxymethyl-4-O-[β-D-galactopyranosyl]-2-O-[2-O-α-D- 
mannopyranosyl]-α-D-mannopyranoside 10. 
To a carbpxymethyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D- 
galactopyranosyl-]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-
mannopyranoside (9) (0.1 g, 0.07 mmol) was dissolved in THF (8 mL) and MeOH 
(0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed into the flask at -78 
oC. Sodium metal was added in several portions until the solution was dark blue. The 
dark blue solution was stirred at -78 oC for 30 min. Following disappearance of the 
dark blue color, EtOH (3 mL) was added and ammonia was blown off with a stream 
of air. The solution was then neutralized with acidic Dowex-resin to pH 7 and the 
resin was filtered off through a Celite pad. The desired (10) was obtained through 
evaporation of solvent under reduced pressure in good yield (31 mg, 78 %).   
1H NMR (CD3OD, 400 MHz): 5.10 (s, 1H), 5.02 (s, 1H), 4.34 (d, 1H, J = 7.6 Hz), 
4.19 (br, 1H), 4.04-3.48 (m, 18H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) 171.0 (C=O), [103.9, 102.7, 99.0 
(CHanomeric)], 77.3, 75.7, 73.8, 73.6, 72.4, 70.6, 69.0, 67.4, 64.0, 61.7, 61.2, 60.8. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C20H34NaO18, 585.1643; Found, 585.6198 
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Synthesis of Carboxymethyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D-
galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl) 
-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside 11. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-
[2,3,4,6,-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-
mannopyranoside (0.2 g, 0.09 mmol) in DCM was bubbled O3 at -78 oC for 5 min. 
The light-blue solution was treated with PPh3 (34 mg, 0.13 mmol) and was allowed to 
warm to room temperature. After 30 min, the crude aldehyde product was obtained 
after concentration under reduced vacuum. To a solution of aldehyde product in 
acetone was added Jones reagent (0.11 mL, 0.08 mmol) and the mixture was stirred 
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for 30 min. After TLC analysis, excess reagent was quenched with 2-propanol and 
sold was filtered off through a Celite pad. The pure product (9) (0.13 g, 85 %) was 
obtained after concentration under reduced vacuum followed by purified through 
silica column chromatography (Hexane:Ethyl Acetate = 1:2). 
Rf (ethyl acetate/haxane): 0.15 (50/50) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.31-7.14 (m, 60H, aromatics), 5.46 (s, 1H), 
5.15 (s, 1H), 4.99 (d, 2H, J = 8 Hz), 4.94 (d, 1H, J = 12 Hz), 4.81 (dd, 2H, J = 8, 4 
Hz), 4.71-4.64 (m, 3H), 4.68 (s, 2H), 4.59-4.56 (m, 3H), 4.51-4.41 (m, 9H), 4.34-4.23 
(m, 5H), 4.13 (d, 1H, J = 16 Hz), 4.00-3.83 (m, 10H), 3.73-3.61 (m, 6H), 3.59-3.50 
(m, 4H), 3.42-3.37 (m, 3H), 2.11 (s, 3H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 173.1, 170.3, [139.3, 139.1, 138.9, 138.8, 
138.7, 138.7, 138.6, 138.6, 138.5, 138.5, 138.3, 138.1 (Cq-Aryl)], 128.6–127.3 (m, 
CH-Aryl), [103.6, 100.6, 99.8, 99.5 (CHanomeric)], 82.8, 80.1, 79.6, 75.6, 75.5, .75.3, 
74.9, 74.8, 74.5, 73.5, 73.5, 73.3, 73.1, 72.9, 72.8, 72.7, 72.4, 72.2 72.1, 68.6, 69.0, 
68.6, 64.5, 21.4. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C112H118NaO24, 1869.7911; Found, 
1870.5026. 
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Synthesis of Carboxymethyl-4-O-[β-D-galactopyranosyl]-2-O-[2-O-(2-O-α-D-
mannopyranosyl)-α-D-mannopyranosyl]-α-D-mannopyranoside 12. 
To a solution of carboxymethyl-3,6-di-O-benzyl-4-O-[2,3,4,6,-tetra-O-benzyl-β-D-
galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside (11) (0.1 g, 0.05 
mmol) was dissolved in THF (8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia 
(20 mL) was then condensed into the flask at -78 oC. Sodium metal was added in 
several portions until the solution was dark blue. The dark blue solution was stirred at 
-78 oC for 30 min. Following disappearance of the dark blue color, EtOH (3 mL) was 
added and ammonia was blown off with a stream of air. The solution was then 
neutralized with acidic Dowex-resin to pH 7 and the resin was filtered off through a 
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Celite pad. The desired (12) was obtained through evaporation of solvent under 
reduced pressure in good yield (36 mg, 90 %).   
1H NMR (CD3OD, 400 MHz): δ (ppm) 5.33 (s, 1H), 5.08 (s, 1H), 4.97 (s, 1H), 4.35 
(d, 1H, J = 7.2 Hz), 4.13 (s, 2H), 4.05-3.96 (4H), 3.85-3.82 (m, 8H), 3.73-3.49(13H).      
13
 C NMR (CD3OD, 100 MHz): δ (ppm) 172.4 (C=O), [103.9, 102.7, 100.9, 98.9 
(CHanomeric)], 79.0, 77.3, 77.3, 75.7, 73.8, 73.6, 73.5, 72.3, 71.3, 71.1, 70.6, 70.6, 69.6, 
69.2, 67.9, 67.4, 63.8, 61.8, 61.3, 60.8. 
HRMS-MALDI (m/z): [M+Na]+Calcd for C26H44NaO23, 747.6035; Found, 747.6172. 
 
Synthesis of sugar-conjugated latex beads 
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R = Lactose (B1), Trimannose (B2)
Branched-tri (B3), Brnched-tetra (B4)
Galactose (B5), Dimmanose (B6)
mmol of COOH per 1mL of beads solution
: (2.7 x 10 10 bead / mL) x  ( 1.296 x x10 -14 mmol/bead) = 3.5 x 10 -4 mmol / mL
  To a solution of latex beads (1mL, 2.7 x 1010 beads/ mL) was added EDC (8 mg, 
0.004 mmol) solution (100 µL) in deionized water (DI water) followed by 
ethylenediamin in MES buffer (200 µL). The reaction mixture was stirred at 26 oC for 
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18 h (X 2) and then beads were washed with DI water 2 ~ 3 times for the Kaiser test. 
10 µL of Beads solution was used to perform a Kaiser test (positive:deep purple color). 
To a solution of sugar (30 equiv of dimannose, trimannose, branched trisaccharide and 
tetrasaccharide; 50 equiv of lactose and galactose) in DI water (200 µL) was added 
EDC solution (DI water, 100 µL) followed by NHS solution (DI water, 100 µL). The 
reaction mixture was stirred for 10 min and then combined with amine-functionalized 
latex beads in MES buffer (200 µL). The mixture was stirred at 26 oC for 18 h (X 2) 
and then performed the Kaiser test with 10 µL of Beads solution (negative: dark 
brown color). Sugar-coated latex beads (2.65 x 1010 beads in 1mL of DI water) were 
stored 4 oC refrigerator.  
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CHAPTER 6 
Modification of degradable polymeric particles with carbohydrates 
for the study of in vitro activation of dendritic cells 
Eun-Ho Song1, Brenda R. Carrillo-Conde2, Balaji Narasimhan2 and Nicola L. Pohl1 
(1) Department of Chemistry, Iowa State University,(2)Department of Chemical and 
Biological Engineering, Iowa State University.  
 
Introduction 
Despite extensive efforts on the development of efficient delivery systems for drugs, 
an efficient carrier for drug to specific areas in the human body has been highlighted 
as a prerequisite for the optimization of drug efficiency.1, 2 More recently, attention 
has been focused on the development of vaccine delivery system in order to prevent 
severe bacterial, viral, parasitic and respiratory infectious diseases both in human and 
animal.3, 4  
Several polymers such as copolymers5 of sebacic anhydride (SA) and 1,6-bis-(p-
carboxyphenoxy)hexane (CPH), copolymers6 of 1,6-bis-(p-carboxyphenoxy)hexane 
(CPH) and 1,8-bis(p-carboxyphenoxy-3,6-dioxaoctane (CPTEG) and 
poly(propylacrylic acid) (PPAA)7 as vaccine delivery vehicles have been extensively 
studied in various biomedical researches due to their biocompatibility and degradation 
properties under certain pH ranges and temperatures.  
Among these polymers, polyanhydride copolymers including CPH:SA and 
CPTEG:CPH have been well characterized in order to facilitate bulk-erodible property, 
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induced by hydrophilic-polymers (CPTEG), into the surface erodible polyanhydrides 
(CPH and SA).8 Important features using polyanhydride copolymers are the 
enhancement of controlling erosion kinetics, determined by a combination of erosion 
mechanisms between bulk-eroding and surface-eroding, for controlled drug release 
kinetics and the non-acidic microenvironment produced by degradation of polymers.5, 
9
 Moreover, recent study with polyanhydride nanoparticles has shown that size and 
chemistry of particles are important factors in cellular internalization of polymers by 
monocytes.10  
To examine carbohydrate antigen-mediated activation of Dendritic cells (DCs), 
more research has been performed with synthetic carbohydrate ligands as antigens 
capable of activating DCs.11 DCs are immune cells that are the most important 
antigen-presenting cells (APCs) in the early stage of immune responses. Importantly, 
DCs are not only capable of stimulating T cells, but also essential for connecting 
innate and adaptive immunities through Th1 cell or Th2 stimulation.12 Although 
importance of carbohydrate antigens has been addressed in terms of immune 
stimulation, accessibility of carbohydrates on polymeric vehicles is still limited by 
lack of suitable conjugation chemistry and degradable property of polymeric particles. 
Previous erosion studies with polyanhydride copolymers showed that 50:50 
CPTEG:CPH copolymer was significantly degraded (67 % of molecular weight loss) 
in water for 2 days.5 This degradation property provides harsh conditions for the 
modification of polymeric particles.   
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In this study, we demonstrated modification of degradable polyanhydride 
copolymers with lactose and dimannose in order to investigate carbohydrate antigen-
dependent immune responses on uptake and activation of DCs.   
  
Results and discussion  
In order to enhance immune responses of copolymers through activation of DCs, 
carbohydrate antigen coated polymers were prepared. 
 
Synthesis of carboxylated-lactose and dimannose. 
Mercury (II)-catalyzed allylation13 of penta-O-acetyl-1-O-bromide lactose using 
Hg(II)CN and all alcohol produced β-1-O-allylated lactose 1 in high yield (92 % three 
steps) as a precursor for oxidation. One-step oxidation of olefin for the construction of 
carboxylic acid in 2-acetamido-2-dexoy-D-glucose has been reported by using 
ruthenium-catalyzed Sharpless conditions.14, 15 As expected, using excess amounts of 
NaIO4 (8 eq) under ruthenium-catalyzed Sharpless conditions produced the desired 
acid 2 in 91 % yield. But, this oxidation is not suitable in the presence of benzyl 
protections due to transformation of benzyl to benzoyl. Subsequent deacetlyation 
under mild condition using K2CO3 provided fully deprotected disaccharide 3.  
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Scheme 1. Synthesis of carboxy-functionalized lactose. 
 
Iterative synthesis of linear α-1,2-linked dimannose 8 has been reported by using 
fluorous-solid phase extraction (FSPE).16 Each glycosylation was performed with 1.1 
equivalent of trichloroacetimidate donor 417 in toluene at 25 oC for 5 min. Facile 
purification of crude product by FSPE enabled easy preparation of desired linear α-
1,2-linked dimannose 8 in high yield.  
 
O
OC8F17
O
BnO
BnO
BnO
OH
O
OC8F17
O
BnO
BnO
BnO
OAc
O
O
BnO
BnO
BnO
OAc
CCl3
NH
(1.1 eqiv.)
1.Deprotection
   (Na, MeOH)
2. Purification
    (FSPE)
1. Couping 
   (TMSOTF, Toluene)
2. Purification
    (FSPE)
n n+1
n = 0 (5)
n = 1 (7) n = 0 (6)n = 1 (8)
4
 
172 
Scheme 2. Iterative synthesis of fluorous–tagged α-1,2-linked dimannose. 
 
Fully deprotected α-1,2-linked dimannose 10 was obtained by ozonolysis18 of 8, 
followed by global deprotection of 9 under Birch reduction conditions19 (Na, NH3). 
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Scheme 3. Synthesis of carboxy-functionalized dimannose. 
 
Modification of micro- and nanoparticles with lactose and dimannose. 
Polyanhydride copolymers5, 6 and FITC-dextran loaded copolymers20 for confocal 
images of the internalization of polymer in DCs were prepared as reported in 
literatures.  
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- Micro-beads (10 ~ 15 um) : 6.69 x 10-4 COOH/mg
- Nano-beads (200 ~ 600 nm) : 9.59 x 10-4 COOH/mg
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Scheme 4. Modification of polymeric particles with carbohydrates. 
 
Surface modification of polymeric particles is obviously challenging due to physical 
properties of polymers such as degradation and aggregation. In addition, FITC-
labeling can be detached from particles during coupling steps under certain conditions 
such as high temperature and organic solvent because it is not chemically attached to 
polymeric particles.19 To overcome these unfavorable properties of polymeric 
particles, optimization of coupling reaction conditions should be a prerequisite for 
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homogeneous density of carbohydrates on the surface.   
Sugar coated polymeric particles were synthesized from carboxylic acid-
functionalized lactose 3 and dimannose 10 using a procedure that has been used for 
the peptide-type coupling reaction. The control compound, glycolic acid, was also 
carried through same steps to work out a viable protocol (Scheme 1). In order to avoid 
fast degradation of polymeric particles, we performed coupling reactions under 
aqueous conditions rather than under DMF or DCM which is common solvent for 
solid-phase synthesis. Although 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC)21 has been used as a coupling agent for the purpose of forming 
amide bonds in peptide synthesis, amine reactive O-acylisourea intermediate which is 
activated by EDC can be hydrolyzed by water. In order to increase the efficiency of 
coupling reaction in aqueous condition, we added N-hydroxysuccinimide (NHS)22 to 
form an amine reactive NHS-ester after activating carboxyl group with EDC. 
Ethlylenediamine as a spacer molecule was attached to carboxylated polymeric 
particles in order to increase accessibility of carbohydrates to the surface of particles. 
Peptide-type coupling reaction was repeated twice with relatively short reaction time 
(8 ~ 9 hours) to accomplish a complete coupling reaction. Carbohydrate-coated 
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polymeric particles were prepared through second coupling reaction with carboxylic 
acid-functionalized lactose 3 and dimannose 10 followed by dry under high-vacuum. 
The Kaiser test23 (Ninhydrin color test) was employed as an indicator of coupling 
reaction progress. Quantitative monitoring of reaction can verify sugar loading on the 
beads.24 Surface characterization by X-ray photoelectron spectroscopy (XPS) clearly 
showed an increase of N/C % in carbohydrate modified particles. (by Brenda R. 
Carrillo-Conde). 
In order to evaluate the effect of surface modification with carbohydrate on immune 
responses, DC activation studies such as cell surface marker expression analysis, 
cytokine production analysis and particle uptake studies have been done by 
collaboration partner (Brenda R. Carrillo-Conde) in Chem. Eng. (Dr. Balaji 
Narasimhan). Although significant difference between unmodified particles and 
carbohydrate-modified particles was not observed in cytokine production studies, 
carbohydrate-modified particles showed higher up-regulation in the expression of 
MHC II, CD40, CD86, CD206, and CD209 as well as greater uptake of lactose by 
DCs, a marker for DC stimulation. Because cells that are associated with immune 
system, display a unique set of cell surface markers, identification of cell surface 
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markers plays a significant role in unveiling the type of immune response.  
 
Conclusion 
We demonstrated that the Surface modification of erodible polymeric particles by 
carbohydrates including lactose and dimannose could play an important role in 
activation of innate immunity. Conjugation chemistry using EDC and NHS provided a 
viable route of modification of erodible polymeric beads without significant loss of 
polymeric particles caused by degradation. 
  Importantly, we observed that carbohydrate-modified particles are closely related 
with several important cell surface markers that are capable of inducing adaptive 
immunity (MHC II, CD40, and CD86) or acting as a cell adhesion receptor (CD209). 
These preliminary results showed great promise for the study of the effect 
carbohydrate-modified particles on the regulation of immune responses.  
In order to support to these results, using branched-/linear trisaccharide and longer 
spacer might be helpful to clarify carbohydrate antigen effect on immune responses 
 
Experimental section 
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General methods 
Solvents were reagent grade and in most cases dried prior to use. All other 
commercially available reagents were used as received unless otherwise noted. The 
organic extracts were dried over anhydrous MgSO4. Tetrahydrofuran (THF) was 
distilled from lithium aluminum hydride (LiAlH4) prior to use. Methylene chloride 
(CH2Cl2), and triethylamine (Et3N) were distilled from calcium hydride. Diethyl ether 
(Et2O) was distilled from sodium-benzophenone ketyl.  
 
1H and 13C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-
400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an 
Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems 
QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per 
million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are 
reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.   
 
Synthesis of carboxylated-lactose and dimannose. 
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Synthesis of Carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl]-
2,3,6-tri-O-acetyl-β-D-galactopyranoside 2. 
To a solution of 2-propynyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl] - 
2,3,6- tri-O-acetyl-β-D-galacto-pyranoside (1)25 (0.5g, 0.7 mmol) in the mixture of 
CCl4 (3 mL), CH3CN (3 mL), and H2O (4 mL) is added NaIO4 (1.27 g, 5.6 mmol). To 
this mixture was added RuCl3.H2O (3.1 mg, 2.2 mol %) and the reaction mixture was 
stirred at 25 oC for 2 h. After dilution with 10 mL of DCM, the reaction mixture was 
filtered through a Celite pad. The aqueous layer was extracted with twice with DCM 
and then organic layer was washed with water and brine. The crude mixture was 
obtained after drying with Na2SO4 followed by concentration under reduced vacuum. 
The crude product was purified to obtain the desired product (2) (0.47 g, 91 %) by 
silica column chromatography 
Rf (ethyl acetate/haxane): 0.30 (70/30) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 5.34 (d, 1H, J = 2.4 Hz), 5.22 (t, 1H, J = 9.2 
Hz), 5.09 (t, 1H, J = 8 Hz), 4.97-4.93 (m, 2H), 4.62 (d, 1H, J = 7.6 Hz), 4.50-4.47 (m, 
2H), 4.29 (s, 2H), 4.11-4.04 (m, 3H), 3.87 (t, 1H, J = 6.4 Hz), 3.80 (t, 1H, J = 9.2 Hz), 
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3.65-3.61 (m, 1H), 2,14 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 
2.03 (s, 3H), 1.93 (s, 3H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 170.6, 170.6, 170.3, 170.3, 170.1, 169.9, 
169.2, [101.2, 100.4 (CHanomeric)], 76.2, 73.1, 72.5, 71.4, 71.1, 70.9, 69.2, 66.8, 65.5, 
61.9, 61.0, 21.0, 21.0, 20.9, 20.9, 2.08, 20.7.  
HRMS-MALDI (m/z): [M+Na]+Calcd for C28H38NaO20, 717.5791; Found, 717.6184. 
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Synthesis of Carboxymethyl-4-O-(β-D-galactopyranosyl)-β-D glucopyranoside 
3.
To a carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl]-2,3,6-tri-O-
acetyl-β-D-galacto-pyranoside (2) (0.4 g, 0.57 mmol) in MeOH (5 mL) was added Na 
(27 mg, 1.14 mmol) and stirred at 25 oC for 2 h. The reaction mixture was neutralized 
with Dowex-ion-exchange resin. The desired (3) was obtained through Celite 
filteration followed by evaporation of solvent under reduced pressure in good yield 
(0.21 g, 89 %).  
1H NMR (CDCl3, 400 MHz): δ (ppm) 4.46 (d, 1H, J = 16.4 Hz), 4.30-4.23 (m, 2H), 
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3.81 (d, 1H, J = 3.2 Hz). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 173.0, 170.8, 170.5, 17.4, 170.2, 100.4 
(CHanomeric), 71.1, 70.7, 68.6, 67.1, 65.0, 61.4, 21.0, 20.9, 20.8, 20.8. 
HRMS-ESI (m/z): [M+Na]+Calcd for C14H24NaO13, 423.1115; Found, 423.0942. 
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Synthesis of Carboxymethyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside 9. 
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-
acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (8) (0.2 g, 
0.15 mmol) in DCM was bubbled O3 at -78 oC for 5 min. The light-blue solution was 
treated with PPh3 (58 mg, 0.23 mmol) and was allowed to warm to room temperature. 
After 30 min, the crude aldehyde product was obtained after concentration under 
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reduced vacuum. To a solution of aldehyde product in acetone was added Jones 
reagent (0.16 mL, 0.13 mmol) and the mixture was stirred for 30 min. After TLC 
analysis, excess reagent was quenched with 2-propanol and sold was filtered off 
through a Celite pad. The pure product (9) (0.12 g, 89 %) was obtained after 
concentration under reduced vacuum followed by purified through silica column 
chromatography (Hexane:Ethyl Acetate = 1:2). 
Rf (ethyl acetate/haxane): 0.30 (70/30) 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.33-7.15 (m, 30H), 5.52 (s, 1H), 5.07 (s, 1H), 
4.98 (s, 1H), 4.83 (dd, 2H, J = 10.8, 6 Hz), 4.68 (s, 2H), 4.67-4.60 (m, 3H), 4.53-4.39 
(m, 5H), 4.10-4.02 (m, 3H), 3.96-3.90 (m, 3H), 3.80-3.65 (m, 7H), 2.11 (s, 3H). 
13
 C NMR (CDCl3, 100 MHz): δ (ppm) 173.5 (C=O), 170.5 (C=O), [138.7, 138.6, 
138.4, 138.3 (Cq-Aryl)], 128.7-127.8 (m, CH-Aryl), [99.8, 99.0 (CHanomeric)], 79.7, 
78.4, 75.4, 74.7, 73.7, 73.6, 72.7, 72.4, 72.3, 72.2, 69.4, 69.2, 69.1, 63.7, 21.4 (CH3). 
HRMS-MALDI (m/z): [M+Na]+Calcd for C58H62NaO14, 1005.4037; Found, 
1005.4289 
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Synthesis of Carboxymethyl-2-O-(2-O-α-D-mannopyranosyl)-α-D- 
mannopyranoside 10. 
To a carboxymethyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-α-D-mannopyranoside (9) (0.1 g, 0.11 mmol) was dissolved in THF 
(8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed 
into the flask at -78 oC. Sodium metal was added in several portions until the solution 
was dark blue. The dark blue solution was stirred at -78 oC for 30 min. Following 
disappearance of the dark blue color, EtOH (3 mL) was added and ammonia was 
blown off with a stream of air. The solution was then neutralized with acidic Dowex-
resin to pH 7 and the resin was filtered off through a Celite pad. The desired (10) was 
obtained through evaporation of solvent under reduced pressure in good yield (34 mg, 
75 %).   
1H NMR (CD3OD, 400 MHz): δ (ppm) 5.15 (s, 1H), 4.98 (s, 1H), 4.24 (m, 2H), 
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3.96-3.57 (m, 12H). 
13
 C NMR (CD3OD, 100 MHz): δ (ppm) 172.3 (C=O), [102.9, 98.7 (CHanomeric)], 
78.8, 78.8, 74.0, 73.7, 71.2, 70.6, 67.4, 63.7, 63.4, 61.8, 61.7. 
HRMS-ESI (m/z): [M+Na]+Calcd for C14H24NaO13, 423.1115; Found, 423.0923. 
 
Modification of polymeric particles with sugars. 
 
- Micro-beads (10 ~ 15 um) : 6.69 x 10-4 COOH/mg
- Nano-beads (200 ~ 600 nm) : 9.59 x 10-4 COOH/mg
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R = Lactose and Dimannose
 
  To a solution of microshperes (20 mg, 1.34 x 10 -2 mmol of COOH) was added 
EDC (31 mg, 0.16 mmol: 12 eq) solution (100 µL) in deionized water (DI water) and 
NHS (19 mg, 0.16 mmol) solution (DI water, 100 µL) followed by ethylenediamin 
(8.9 µL, 0.13 mmol: 10 eq) in DI water (100 µL). The reaction mixture was stirred at 
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25 oC for 8 ~ 9 h (X 2) and then microspheres were washed with DI water 2 ~ 3 times 
for the Kaiser test. 1 mg of particles was used to perform a Kaiser test (positive:deep 
purple color). To a solution of sugar (53 mg, 0.13 mmol: 10 eq) in DI water (200 µL) 
was added EDC (31 mg, 0.16 mmol) solution (100 µL of DI water) followed by NHS 
(19 mg, 0.16 mmol) solution (DI water, 100 µL). The reaction mixture was stirred for 
10 min and then combined with amine-functionalized particles in DI water (200 µL, 
pH = 9). The mixture was stirred at 25 oC for 8 ~ 9 h (X 2) and then performed the 
Kaiser test with 1 mg of particles (negative: dark brown color). Di water was removed 
and wet sugar-coated particles were dried under high vacuum. (Particle aggregation 
was prevented by using probe sonicator during coupling reaction.) 
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CHAPTER 7 
 
Conclusions and Future Directions 
In this dissertation, the first automated solution-phase syntheses of oligosaccharides 
that are related to infectious disease such as HIV, leishmaniasis and tuberculosis are 
reported. The use of a new fluorous-based automation platform enabled the facile 
synthesis of HIV-associated linear α-(1,2)-pentamannose as well as a Leishmania-
capping tetrasaccharide. In addition, chemistry for the construction of phosphate-
linked sugars was successively programmed and applied to the synthesis of 
lipophosphoglycans associated with Leishmania. The new automated methods 
developed herein and featured in the construction of complicated oligosaccharides not 
only opens up a new era for oligosaccharide library synthesis—capable of facilitating 
diversity both in structure and sequence—but also easier access to carbohydrates for 
systematic structure-function relationship studies. The combination of the fluorous-
based automation platform with fluorous-based microarrays should be a powerful tool 
for accelerating research progress in glycomics.  
In addition to the development of automated methods for the synthesis of several 
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bioactive oligosaccharides, this thesis demonstrates the importance of systematic 
structure-function evaluations for carbohydrate structures in understanding innate 
immune responses to these structures. Methods to attach synthetic sugars to latex 
beads or erodable polymeric particles for multivalent displays are reported. 
Collaborative studies show that these synthetic structures exhibit clear differences in 
the activation of innate immune responses based solely on differences in the 
carbohydrate structure. Further studies on the effect of carbohydrate structures on 
immune responses will aid the development of carbohydrate-based antigens as 
vaccine adjuvants and vaccines. Future studies should also aim to evaluate the 
immunomodulatory effects of structurally different cap sugars in vivo. Ultimately, 
significant progress both in the synthetic tools available and in the study of immunity 
induced by carbohydrates will provide the necessary background to fully develop and 
evaluate the therapeutic potential of carbohydrate-based vaccines as 
immunomodulatory adjuvants.  
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APPENDIX A. 
CHAPTER 2 1H AND 13C NMR SPECTRA 
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APPENDIX B. 
CHAPTER 3 1H AND 13C NMR SPECTRA 
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APPENDIX C. 
CHAPTER 4 1H AND 13C NMR SPECTRA 
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